Paul Schulwitz

Access DB# 164246

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Rebecca Cook Examiner #: 69826 Date: 8/29/05

Art Unit: 1614 Phone Number 30 Serial Number: 10/623577

Mail Box and Bldg/Room Location: 3C70 Results Format Preferred (circle): PAPER DISK E-MAIL

3A71

If more than one search is submitted, please prioritize searches in order of need. MEJ

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: _____

Inventors (please provide full names): See attached

_____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search compound of claim 1 in any formulation; in solution, in oral solution in suitable data bases.

Thanks

Rebecca

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable	
Searcher:	NA Sequence (#)		STN	
Searcher Phone #:	AA Sequence (#)		Dialog	
Searcher Location:	Structure (#)		Questel/Orbit	
Date Searcher Picked Up:	Bibliographic		Dr.Link	
Date Completed:	Litigation		Lexis/Nexis	
Searcher Prep & Review Time:	Fulltext		Sequence Systems	
Clerical Prep Time:	Patent Family		WWW/Internet	
Online Time	Other		Other (specify)	

PTO-1590 (8-01)

THIS PAGE IS BLANK

=> d his ful

```
     (FILE 'HOME' ENTERED AT 18:12:02 ON 14 SEP 2005)

     FILE 'REGISTRY' ENTERED AT 18:12:06 ON 14 SEP 2005
L1             STR
L2           8 SEA SSS SAM L1
L3         314 SEA SSS FUL L1

     FILE 'HCAPLUS' ENTERED AT 18:14:19 ON 14 SEP 2005
L4         703 SEA ABB=ON  PLU=ON  L3

     FILE 'REGISTRY' ENTERED AT 18:14:23 ON 14 SEP 2005
L5             STR L1
L6          11 SEA SUB=L3 SSS SAM L5
L7         265 SEA SUB=L3 SSS FUL L5

     FILE 'HCAPLUS' ENTERED AT 18:15:25 ON 14 SEP 2005
L8         702 SEA ABB=ON  PLU=ON  L7

     FILE 'REGISTRY' ENTERED AT 18:15:31 ON 14 SEP 2005
L9             STR L5
L10          4 SEA SUB=L3 SSS SAM L9
L11        135 SEA SUB=L3 SSS FUL L9

     FILE 'HCAPLUS' ENTERED AT 18:16:20 ON 14 SEP 2005
L12        702 SEA ABB=ON  PLU=ON  L11

     FILE 'REGISTRY' ENTERED AT 18:16:34 ON 14 SEP 2005
L13            STR L9
L14         52 SEA SUB=L3 SSS FUL L13

     FILE 'HCAPLUS' ENTERED AT 18:17:58 ON 14 SEP 2005
L15        700 SEA ABB=ON  PLU=ON  L14

     FILE 'REGISTRY' ENTERED AT 18:18:08 ON 14 SEP 2005
L16            STR L13
L17         22 SEA SUB=L3 SSS FUL L16

     FILE 'HCAPLUS' ENTERED AT 18:19:18 ON 14 SEP 2005
L18        697 SEA ABB=ON  PLU=ON  L17

     FILE 'REGISTRY' ENTERED AT 18:19:27 ON 14 SEP 2005

     FILE 'HCAPLUS' ENTERED AT 18:19:46 ON 14 SEP 2005
               E US2003-623577/APPS
L19          2 SEA ABB=ON  PLU=ON  US2003-623577/AP
               SEL RN

     FILE 'REGISTRY' ENTERED AT 18:20:34 ON 14 SEP 2005
L20         27 SEA ABB=ON  PLU=ON  (1668-85-5/BI OR 321-64-2/BI OR 357-70-0/BI
                OR 41303-74-6/BI OR 9001-08-5/BI OR 101246-68-8/BI OR
                120011-70-3/BI OR 120014-06-4/BI OR 120014-07-5/BI OR 120014-08
                -6/BI OR 120014-09-7/BI OR 120014-10-0/BI OR 120014-11-1/BI OR
                120014-12-2/BI OR 120014-13-3/BI OR 16088-19-0/BI OR 172602-64-
                1/BI OR 1953-04-4/BI OR 359785-78-7/BI OR 359785-79-8/BI OR
                475473-11-1/BI OR 50-23-7/BI OR 51581-32-9/BI OR 52-68-6/BI OR
                57-47-6/BI OR 86697-68-9/BI OR 9000-81-1/BI)
```

```
     FILE 'HCAPLUS' ENTERED AT 18:20:39 ON 14 SEP 2005
L21            2 SEA ABB=ON  PLU=ON  L19 AND L20
                 D IALL HITSTR 1-2
                 E DRUG DELIVERY SYSTEMS/CT
L22       196614 SEA ABB=ON  PLU=ON  DRUG DELIVERY SYSTEMS+PFT,NT1/CT
L23          601 SEA ABB=ON  PLU=ON  L17(L)(BAC OR DMA OR PAC OR PKT OR THU)/RL

L24          141 SEA ABB=ON  PLU=ON  L22 AND L23
L25          137 SEA ABB=ON  PLU=ON  L24 AND P/DT
L26            4 SEA ABB=ON  PLU=ON  L24 NOT L25
L27            0 SEA ABB=ON  PLU=ON  L26 NOT PY>2000
L28           40 SEA ABB=ON  PLU=ON  L25 NOT PRD>2000
L29          233 SEA ABB=ON  PLU=ON  L8 AND P/DT
L30          469 SEA ABB=ON  PLU=ON  L8 NOT P/DT
L31          158 SEA ABB=ON  PLU=ON  L30 NOT PY>2000
L32           72 SEA ABB=ON  PLU=ON  L29 NOT PRY>2000
L33          230 SEA ABB=ON  PLU=ON  L31 OR L32
L34          608 SEA ABB=ON  PLU=ON  L7(L)(BAC OR DMA OR PAC OR PKT OR THU)/RL
L35          175 SEA ABB=ON  PLU=ON  L33 AND L34
L36           40 SEA ABB=ON  PLU=ON  L35 AND L22


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   13 SEP 2005  HIGHEST RN 863091-33-2
     DICTIONARY FILE UPDATES:  13 SEP 2005  HIGHEST RN 863091-33-2

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     Experimental and calculated property data are now available. For more
     information enter HELP PROP at an arrow prompt in the file or refer
     to the file summary sheet on the web at:
     http://www.cas.org/ONLINE/DBSS/registryss.html

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
```

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Sep 2005 VOL 143 ISS 12
FILE LAST UPDATED: 13 Sep 2005 (20050913/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L3 314 SEA FILE=REGISTRY SSS FUL L1
L5 STR



```
NODE ATTRIBUTES:
CONNECT IS E2  RC AT  13
CONNECT IS E2  RC AT  20
CONNECT IS E1  RC AT  27
CONNECT IS E1  RC AT  28
DEFAULT MLEVEL IS ATOM
GGCAT   IS LIN  LOC  SAT  AT  13
GGCAT   IS LIN  LOC  SAT  AT  20
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  28

STEREO ATTRIBUTES: NONE
L7          265 SEA FILE=REGISTRY SUB=L3 SSS FUL L5
L8          702 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7
L22      196614 SEA FILE=HCAPLUS ABB=ON  PLU=ON  DRUG DELIVERY SYSTEMS+PFT,NT1/
                CT
L29         233 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L8 AND P/DT
L30         469 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L8 NOT P/DT
L31         158 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L30 NOT PY>2000
L32          72 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L29 NOT PRY>2000
L33         230 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L31 OR L32
L34         608 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7(L)(BAC OR DMA OR PAC OR
                PKT OR THU)/RL
L35         175 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L33 AND L34
L36          40 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L35 AND L22


=> d l36 ibib abs hitstr 1-40

L36  ANSWER 1 OF 40  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2002:330207  HCAPLUS
DOCUMENT NUMBER:          136:350581
TITLE:                    Combinations of D4 dopamine receptor antagonists with
                          acetylcholinesterase inhibitors for the treatment of
                          dementia or cognitive deficits associated with
                          Alzheimer's Disease or Parkinson's Disease
INVENTOR(S):              Fliri, Anton Franz Josef; Sanner, Mark Allen; Zorn,
                          Stevin Howard
PATENT ASSIGNEE(S):       Pfizer Products Inc., USA
SOURCE:                   Eur. Pat. Appl., 36 pp.
                          CODEN: EPXXDW
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     EP 1201268            A2    20020502    EP 2001-308953          20011022
     EP 1201268            A3    20040102
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     US 2002052373         A1    20020502    US 2001-931551          20010816
     CA 2359877            AA    20020426    CA 2001-2359877         20011024
     BR 2001004830         A     20020528    BR 2001-4830            20011026
     JP 2003063994         A2    20030305    JP 2001-328863          20011026
```

PRIORITY APPLN. INFO.: US 2000-243543P P 20001026
OTHER SOURCE(S): MARPAT 136:350581

AB The invention discloses a method of treating dementia or cognitive deficits associated with Alzheimer's disease or Parkinson's disease in a mammal, including a human, by administering to the mammal a D4 dopamine receptor antagonist in combination with an acetylcholinesterase inhibitor. Also disclosed are pharmaceutical compns. containing a pharmaceutically acceptable carrier, a D4 dopamine receptor antagonist and an acetylcholinesterase inhibitor.

IT **120014-06-4 120014-07-5 120014-09-7 120014-11-1 120014-13-3 120014-14-4 120014-15-5**
RL: **PAC (Pharmacological activity)**; **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(D4 dopamine receptor antagonist-acetylcholinesterase inhibitor combination for treatment of dementia or cognitive deficit associated with Alzheimer's or Parkinson's disease)

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 120014-07-5 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methylene]- (9CI) (CA INDEX NAME)



RN 120014-09-7 HCAPLUS
CN 1H-Inden-1-one, 5,6-diethoxy-2,3-dihydro-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 120014-11-1 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-[(3-nitrophenyl)methyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 120014-13-3 HCAPLUS
CN 1H-Inden-1-one, 2-[[1-[(3-fluorophenyl)methyl]-4-piperidinyl]methyl]-2,3-dihydro-5,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 120014-14-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]- (9CI) (CA INDEX NAME)



RN 120014-15-5 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-6-methoxy-5-(1-methylethoxy)-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L36 ANSWER 2 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:31416 HCAPLUS
DOCUMENT NUMBER: 136:102292
TITLE: Preparation of piperidine derivatives as agents for controlling intraocular pressure
INVENTOR(S): Iimura, Yoichi; Kosasa, Takashi; Kato, Akira
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002526	A1	20020110	WO 2001-JP5714	20010702

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2000-200899 A 20000703
JP 2000-230319 A 20000731

OTHER SOURCE(S): MARPAT 136:102292

GI



AB The title compds. R1MAR2 (I) [R1 is (un)substituted 1-indanone-2-yl moiety (generic structure given), etc.; M is single bond or alkylene; A = Q1, etc.; R2 is hydrogen, optionally substituted alkyl, etc.] are prepared I are useful in the treatment, prevention or amelioration of eye diseases such as glaucoma and mydriasis. I are said to show intraocular pressure-decreasing activity and acetylcholine esterase inhibiting activity. For example, 1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanone)-2-yl]methylpiperidine hydrochloride was prepared Formulations are given.

IT **178551-26-3P 231283-82-2P 290308-78-0P**
290308-79-1P 290308-81-5P 290308-82-6P
290308-83-7P 290308-90-6P 290308-91-7P
290308-92-8P 290308-95-1P 290308-96-2P
290309-01-2P 290309-02-3P 290309-03-4P
290309-04-5P 290309-05-6P 290309-06-7P
290309-07-8P 290309-08-9P 290309-09-0P
290309-10-3P 290309-11-4P 290309-12-5P
307307-69-3P 307307-70-6P 388115-04-6P
388115-05-7P 388115-07-9P 388115-12-6P
388115-15-9P 388115-16-0P 388115-17-1P
388115-18-2P 388115-19-3P 388115-20-6P
388115-21-7P
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine derivs. as agents for controlling intraocular pressure)

RN 178551-26-3 HCAPLUS

CN Pyridinium, 4-[(1,3-dihydro-5,6-dimethoxy-1-oxo-2H-inden-2-ylidene)methyl]-1-(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 231283-82-2 HCAPLUS
CN Pyridinium, 4-[(2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1-(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 290308-78-0 HCAPLUS
CN 1H-Inden-1-one, 5,6-diethoxy-2-fluoro-2,3-dihydro-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290308-79-1 HCAPLUS
CN 1H-Inden-1-one, 5,6-diethoxy-2-fluoro-2,3-dihydro-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 290308-81-5 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 290308-82-6 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2-[[1-[(3-fluorophenyl)methyl]-4-piperidinyl]methyl]-2,3-dihydro-5,6-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290308-83-7 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2-[[1-[(3-fluorophenyl)methyl]-4-piperidinyl]methyl]-2,3-dihydro-5,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 290308-90-6 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[[1-[[4-(phenylmethoxy)phenyl]methyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 290308-91-7 HCAPLUS

CN Benzonitrile, 3-[[4-[(2-fluoro-2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290308-92-8 HCAPLUS
CN Benzonitrile, 3-[[4-[(2-fluoro-2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 290308-95-1 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[[1-[(3-nitrophenyl)methyl]-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290308-96-2 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[[1-[(3-nitrophenyl)methyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 290309-01-2 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290309-02-3 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]- (9CI) (CA INDEX NAME)



RN 290309-03-4 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-2-[[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]methyl]-5,6-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290309-04-5 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-2-[[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]methyl]-5,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 290309-05-6 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-2-[[1-[[2-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]methyl]-5,6-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290309-06-7 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-2-[[1-[[2-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]methyl]-5,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 290309-07-8 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-5,6-dipropoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290309-08-9 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-5,6-dipropoxy- (9CI) (CA INDEX NAME)



RN 290309-09-0 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2-[[1-[(2-fluorophenyl)methyl]-4-piperidinyl]methyl]-2,3-dihydro-5,6-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290309-10-3 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2-[[1-[(2-fluorophenyl)methyl]-4-piperidinyl]methyl]-2,3-dihydro-5,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 290309-11-4 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2-[[1-[(4-fluorophenyl)methyl]-4-piperidinyl]methyl]-2,3-dihydro-5,6-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 290309-12-5 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2-[[1-[(4-fluorophenyl)methyl]-4-

piperidinyl]methyl]-2,3-dihydro-5,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 307307-69-3 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 307307-70-6 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 388115-04-6 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[[1-[(4-methylphenyl)methyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 388115-05-7 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[[1-[(4-methylphenyl)methyl]-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 388115-07-9 HCAPLUS
CN 1H-Inden-1-one, 2-fluoro-2,3-dihydro-5,6-dimethoxy-2-[[1-[[4-(phenylmethoxy)phenyl]methyl]-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 388115-12-6 HCAPLUS
CN Pyridinium, 4-[(2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1-(phenylmethyl)-, chloride (9CI) (CA INDEX NAME)



● Cl^-

RN 388115-15-9 HCAPLUS
CN Pyridinium, 4-[2-(2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)ethyl]-1-(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 388115-16-0 HCAPLUS
CN Pyridinium, 4-[3-(2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)propyl]-1-(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 388115-17-1 HCAPLUS
CN Pyridinium, 4-[(2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1-[(3-fluorophenyl)methyl]-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 388115-18-2 HCAPLUS
CN Pyridinium, 4-[(2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1-[(3-methylphenyl)methyl]-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 388115-19-3 HCAPLUS
CN Pyridinium, 4-[(2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1-[(4-hydroxyphenyl)methyl]-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 388115-20-6 HCAPLUS
CN Pyridinium, 4-[(2-fluoro-2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1-(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)



● Br^-

RN 388115-21-7 HCAPLUS
CN Pyridinium, 4-[(2-fluoro-2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1-[(4-hydroxyphenyl)methyl]-, bromide (9CI) (CA INDEX NAME)



IT **120014-06-4 120014-09-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of piperidine derivs. as agents for controlling intraocular pressure)
RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 120014-09-7 HCAPLUS
CN 1H-Inden-1-one, 5,6-diethoxy-2,3-dihydro-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



IT **290308-69-9P 290308-71-3P 290308-72-4P**
290308-73-5P 290308-74-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperidine derivs. as agents for controlling intraocular pressure)
RN 290308-69-9 HCAPLUS
CN Benzonitrile, 3-[[4-[(2,3-dihydro-5,6-dimethoxy-1-oxo-1H-inden-2-yl)methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 290308-71-3 HCAPLUS
CN 1H-Inden-1-one, 2-[[1-[[2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]phenyl]methyl]-4-piperidinyl]methyl]-2,3-dihydro-5,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 290308-72-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-2-[[1-[[2-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]methyl]-5,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 290308-73-5 HCAPLUS
CN 1H-Inden-1-one, 2-[[1-[[2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]phenyl]methyl]-4-piperidinyl]methyl]-2-fluoro-2,3-dihydro-5,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 290308-74-6 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-5,6-dipropoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 3 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:868188 HCAPLUS
DOCUMENT NUMBER: 135:376700
TITLE: Transdermal therapeutic system for application of active agents directly via the carotid artery or via superficial branches of the iliac or subclavian arteries
INVENTOR(S): Otto, Karlheinz; Selzer, Torsten; Kiehnle, Axel
PATENT ASSIGNEE(S): LTS Lohmann Therapie-Systeme A.-G., Germany
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001089489	A2	20011129	WO 2001-EP5475	20010515
WO 2001089489	A3	20020502		
W: JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
DE 10025644	A1	20011206	DE 2000-10025644	20000524

PRIORITY APPLN. INFO.: DE 2000-10025644 A 20000524

AB The invention relates to the transdermal application of active agents in the region of the carotid artery or the superficial branches of the iliac or subclavian arteries. Narrow and/or ribbon-type transdermal therapeutic systems (TTS), which are applied to the course of the carotid artery and the superficial branches of the iliac or subclavian arteries, are particularly suitable for the application. The aim of this type of application is to ensure that active agents selectively reach the corresponding target tissue or areas to be treated as quickly as possible. The invention also relates to the use of the TTS for medical application in various indications. Thus a plaster was prepared by mixing 50 g Selegiline, 20 g permeation enhancer (Brij) and 200 g 1,2-propanediol; the mixture was dispersed in silicon adhesive 4301 from Dow Corning; the dispersion was used to coat a polyethylene terephthalate foil.

IT **120014-06-4**, Donepezil
RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(transdermal therapeutic system for application of active agents directly via carotid artery or via superficial branches of iliac or subclavian arteries)

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L36 ANSWER 4 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:833859 HCAPLUS
DOCUMENT NUMBER: 135:352826
TITLE: Dialkylaminoalkoxy group-substituted triphenylethylenes for increasing brain levels of acetylcholine and improving memory in acetylcholine-deficient brain states
INVENTOR(S): Bryant, Henry Uhlman; Paul, Steven Marc; Wu, Xin; Glinn, Michele Annette
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2001041745	A1	20011115	US 2000-537426		20000327
PRIORITY APPLN. INFO.:			US 1999-128322P	P	19990408
			US 1999-133700P	P	19990512

OTHER SOURCE(S): MARPAT 135:352826
AB Dialkylaminoalkoxy group-substituted triphenylethylenes (I) are used for up-regulating choline acetyltransferase in mammals so as to increase the amount of acetylcholine present and thus improve memory in acetylcholine-deficient brain diseases; a I-formulation is presented.
IT **120011-70-3**, Donepezil hydrochloride
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(dialkylaminoalkoxy group-substituted triphenylethylene cognition enhancer formulations containing)
RN 120011-70-3 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L36 ANSWER 5 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:791870 HCAPLUS
DOCUMENT NUMBER: 135:322758
TITLE: Manufacture of oral powder compositions containing stearate lubricants
INVENTOR(S): Owaki, Takayuki; Morita, Yutaka; Yasui, Masanobu; Tsushima, Yuki
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001302497	A2	20011031	JP 2000-120708	20000421

PRIORITY APPLN. INFO.: JP 2000-120708 20000421

AB This invention relates to easily miscible powder compns. to facilitate oral administration of drugs with unpleasant tastes. The prepns. comprise (1) ≥ 2 powder compns. containing sustained-release drug microgranular forms and sweetener-containing powders and (2) Ca stearate and/or Mg stearate. The claimed drugs for these prepns. include ticlopidine·HCl, donepezil·HCl, etilefrine·HCl, diltiazem·HCl, propranolol·HCl, indeloxazine·HCl, and aminoguanidine·HCl.

IT **120011-70-3**, Donepezil hydrochloride
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(easily miscible oral powder compns. containing stearate lubricants)

RN 120011-70-3 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L36 ANSWER 6 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:551853 HCAPLUS
DOCUMENT NUMBER: 135:127222
TITLE: Rapidly disintegrable solid formulations containing multiporous polymer matrixes
INVENTOR(S): Thombre, Avinashi Govindo; Wigman, Larry Steven
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001206841	A2	20010731	JP 2001-11348	20010119
EP 1120109	A2	20010801	EP 2001-300330	20010116

EP 1120109 A3 20020710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
US 2002034542 A1 20020321 US 2001-764929 20010118
US 6497899 B2 20021224
CA 2331719 AA 20010724 CA 2001-2331719 20010122
BR 2001000145 A 20010828 BR 2001-145 20010124
PRIORITY APPLN. INFO.: US 2000-178041P P 20000124

AB The title formulations comprise (1) pharmaceutically acceptable vapor-extruded polymers selected from the group consisting of starch, gelatin, dextran, dextrin, alginic acid salts, and hydroxypropyl Me cellulose and (2) amorphous active ingredients. The formulations are preferably in the forms of tablets or suppositories.

IT **120011-70-3**, Donepezil hydrochloride
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(rapidly disintegrable solid prepns. containing vapor-extruded polymer matrixes)

RN 120011-70-3 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L36 ANSWER 7 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:396644 HCAPLUS
DOCUMENT NUMBER: 135:24671
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6248363	B1	20010619	US 1999-447690	19991123
CA 2391923	AA	20010531	CA 2000-2391923	20001122
EP 1233756	A1	20020828	EP 2000-980761	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003517470	T2	20030527	JP 2001-539423	20001122
PRIORITY APPLN. INFO.:			US 1999-447690 A	19991123
			WO 2000-US32255 W	20001122

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A composition contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IT **120014-06-4**, Donepezil
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

RN 120014-06-4 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 8 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2001:300514 HCAPLUS
DOCUMENT NUMBER:	134:331617
TITLE:	Oil-in-water emulsion compositions for polyfunctional active ingredients
INVENTOR(S):	Chen, Feng-jing; Patel, Mahesh V.
PATENT ASSIGNEE(S):	Lipocine, Inc., USA
SOURCE:	PCT Int. Appl., 82 pp. CODEN: PIXXD2
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028555	A1	20010426	WO 2000-US28835	20001018
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002107265	A1	20020808	US 1999-420159	19991018
US 6720001	B2	20040413		

PRIORITY APPLN. INFO.: US 1999-420159 A 19991018

AB Pharmaceutical oil-in-water emulsions for delivery of polyfunctional active ingredients with improved loading capacity, enhanced stability, and reduced irritation and local toxicity are described. Emulsions include an aqueous phase, an oil phase comprising a structured triglyceride, and an emulsifier. The structured triglyceride of the oil phase is substantially free of triglycerides having three medium chain (C6-C12) fatty acid moieties, or a combination of a long chain triglyceride and a polarity-enhancing polarity modifier. The present invention also provides methods of treating an animal with a polyfunctional active ingredient, using dosage forms of the pharmaceutical emulsions. For example, an emulsion was prepared, with cyclosporin A as the polyfunctional active ingredient dissolved in an oil phase including a structured triglyceride (Captex 810D) and a long chain triglyceride (safflower oil). The composition contained (by weight) cyclosporin A 1.0, Captex 810D 5.0, safflower oil 5.0, BHT 0.02, egg phospholipid 2.4, dimyristoylphosphatidyl glycerol 0.2, glycerol 2.25, EDTA 0.01, and water up to 100%, resp.

IT **120014-06-4**, Donepezil
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(oil-in-water emulsion compns. for polyfunctional active ingredients)

RN 120014-06-4 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 9 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:246515 HCAPLUS

DOCUMENT NUMBER: 134:261267

TITLE: α-Sulfonylaminohydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders

INVENTOR(S): Sahagan, Barbara Gail; Villalobos, Anabella
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1088550	A1	20010404	EP 2000-308442	20000927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6417229	B1	20020709	US 2000-671435	20000927
ZA 2000005217	A	20020328	ZA 2000-5217	20000928
CA 2321593	AA	20010401	CA 2000-2321593	20000929
JP 2001097854	A2	20010410	JP 2000-298071	20000929

PRIORITY APPLN. INFO.: US 1999-157083P P 19991001
OTHER SOURCE(S): MARPAT 134:261267

AB A method is provided for using the title compds., pharmaceutically acceptable salts thereof, or pharmaceutical compns. thereof, in the treatment of a disease, condition or disorder of the peripheral or central nervous system, including but not limited to Alzheimer's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, migraine, cerebral amyloid angiopathy, AIDS, age-related cognitive decline, mild cognitive impairment and prion diseases.

IT **120014-06-4**, Donepezil
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(α-sulfonylaminohydroxamic acid inhibitors of matrix metalloproteinases for treatment of nervous system disorders, and use with other agents)

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 10 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:101123 HCAPLUS
DOCUMENT NUMBER: 134:152630
TITLE: Pharmaceutical compositions containing novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen

e hydrochloride
INVENTOR(S): Bush, Julie Kay; Conrad, Preston Charles; Flom, Merlyn Gerard; Luke, Wayne Douglas
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009116	A2	20010208	WO 2000-US16333	20000717
WO 2001009116	A3	20010517		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000063356	A5	20010219	AU 2000-63356	20000717
EP 1204656	A2	20020515	EP 2000-950223	20000717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
LV 12623	B	20010720	LV 2000-94	20000718
HR 2000000503	A1	20010630	HR 2000-503	20000725
NL 1015821	A1	20010130	NL 2000-1015821	20000727
NL 1015821	C2	20020103		
TR 200002206	A2	20010321	TR 2000-200002206	20000727
CA 2314682	AA	20010129	CA 2000-2314682	20000728
FI 2000001722	A	20010130	FI 2000-1722	20000728
NO 2000003879	A	20010130	NO 2000-3879	20000728
SE 2000002792	A	20010130	SE 2000-2792	20000728
PT 102502	A	20010131	PT 2000-102502	20000728
AU 2000048912	A5	20010201	AU 2000-48912	20000728
AU 780211	B2	20050310		
FR 2796944	A1	20010202	FR 2000-9969	20000728
FR 2796944	B1	20030131		
GB 2352717	A1	20010207	GB 2000-18641	20000728
DE 10036854	A1	20010301	DE 2000-10036854	20000728
JP 2001064277	A2	20010313	JP 2000-228939	20000728
BR 2000003209	A	20010320	BR 2000-3209	20000728
CN 1288007	A	20010321	CN 2000-122237	20000728
MD 20000162	A	20010430	MD 2000-20000162	20000728
MD 2336	F2	20031231		
LT 4790	B	20010525	LT 2000-76	20000728
LU 90617	A2	20010615	LU 2000-90617	20000728
SI 20426	C	20010630	SI 2000-172	20000728
BE 1013411	A3	20011204	BE 2000-478	20000728
IT 2000MI1759	A1	20020128	IT 2000-MI1759	20000728
IT 1318660	B1	20030827		
ZA 2000003837	A	20020128	ZA 2000-3837	20000728
NZ 506046	A	20020328	NZ 2000-506046	20000728
SG 91296	A1	20020917	SG 2000-4288	20000728
GR 1004084	B2	20021211	GR 2000-100265	20000728

GR 2000100265	A	20010330			
RU 2240319	C2	20041120	RU 2000-120575		20000728
HK 1035370	A1	20041217	HK 2001-106204		20010903
US 6653479	B1	20031125	US 2002-31326		20020110
PRIORITY APPLN. INFO.:			US 1999-146286P	P	19990729
			US 1999-147570P	P	19990806
			US 1999-149773P	P	19990819
			WO 2000-US16333	W	20000717

AB The present invention is directed to a novel crystalline hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride (I) and uses for same, including inhibition of disease states associated with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathol. conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimer's disease, prevention of breast cancer, and up-regulating ChAT. Form I of I was prepared by crystallization of arzoxifene from THF. The efficacy of the compound in the treatment of human benign prostatic hyperplasia was studied. A capsule contained form I 1000, starch 650, starch flowable powder 650, and silicon fluid-350 cSt 15 mg.

IT **120011-70-3**, Donepezil hydrochloride
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical composition containing novel crystalline form of arzoxifene)

RN 120011-70-3 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L36 ANSWER 11 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2001:101122 HCAPLUS
DOCUMENT NUMBER:	134:152629
TITLE:	Pharmaceutical composition containing novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
INVENTOR(S):	Bush, Julie Kay; Conrad, Preston Charles; Flom, Merlyn Gerard
PATENT ASSIGNEE(S):	Eli Lilly and Company, USA
SOURCE:	PCT Int. Appl., 57 pp. CODEN: PIXXD2
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001009115	A2	20010208	WO 2000-US16332		20000717
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2000063355	A5	20010219	AU 2000-63355		20000717
EP 1204655	A2	20020515	EP 2000-950222		20000717
EP 1204655	B1	20031001			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
AT 251151	E	20031015	AT 2000-950222		20000717
ES 2208384	T3	20040616	ES 2000-950222		20000717
LV 12733	B	20020220	LV 2000-95		20000718
HR 2000000502	A1	20010630	HR 2000-502		20000725
NL 1015822	A1	20010130	NL 2000-1015822		20000727
NL 1015822	C2	20040804			
TR 200002205	A2	20010321	TR 2000-200002205		20000727
CA 2314685	AA	20010129	CA 2000-2314685		20000728
FI 2000001721	A	20010130	FI 2000-1721		20000728
NO 2000003876	A	20010130	NO 2000-3876		20000728
SE 2000002793	A	20010130	SE 2000-2793		20000728
PT 102501	A	20010131	PT 2000-102501		20000728
AU 2000048911	A5	20010201	AU 2000-48911		20000728
AU 779559	B2	20050127			
GB 2352716	A1	20010207	GB 2000-18636		20000728
CN 1283622	A	20010214	CN 2000-122240		20000728
JP 2001048880	A2	20010220	JP 2000-228949		20000728
BR 2000003211	A	20010313	BR 2000-3211		20000728
FR 2798384	A1	20010316	FR 2000-9972		20000728
FR 2798384	B1	20040924			
DE 10036855	A1	20010322	DE 2000-10036855		20000728
GR 2000100264	A	20010330	GR 2000-100264		20000728
MD 20000161	A	20010430	MD 2000-20000161		20000728
MD 2335	F2	20031231			
LT 4789	B	20010525	LT 2000-75		20000728
SI 20427	C	20010630	SI 2000-173		20000728
BE 1013410	A3	20011204	BE 2000-477		20000728
IT 2000MI1758	A1	20020128	IT 2000-MI1758		20000728
IT 1318659	B1	20030827			
ZA 2000003838	A	20020128	ZA 2000-3838		20000728
NZ 506045	A	20020201	NZ 2000-506045		20000728
SG 90737	A1	20020820	SG 2000-4287		20000728
RU 2240318	C2	20041120	RU 2000-120574		20000728
HK 1034962	A1	20041217	HK 2001-105511		20010808
US 6610706	B1	20030826	US 2002-31324		20020110
PRIORITY APPLN. INFO.:			US 1999-146184P	P	19990729
			US 1999-147642P	P	19990806
			US 1999-149820P	P	19990819
			WO 2000-US16332	W	20000717

AB The present invention is directed to a novel crystalline hydrate of

6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride (I) and uses for same, including inhibition of disease states associated with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathol. conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimer's disease, prevention of breast cancer, and up-regulating ChAT. I was prepared by reaction of boron trichloride with 6-isopropoxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride. The efficacy of the compound in the treatment of human benign prostatic hyperplasia was studied. A capsule contained I 1000, starch 650, starch flowable powder 650, and silicon fluid 350-cSt 15 mg.

IT **120011-70-3**, Donepezil hydrochloride
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical composition containing novel crystalline form of arzoxifene)

RN 120011-70-3 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L36 ANSWER 12 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:861473 HCAPLUS
DOCUMENT NUMBER: 134:32972
TITLE: Porous drug matrixes containing polymers and sugars and methods of their manufacture
INVENTOR(S): Straub, Julie; Bernstein, Howard; Chickering, Donald E., III; Khatak, Sarwat; Randall, Greg
PATENT ASSIGNEE(S): Acusphere, Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000072827	A2	20001207	WO 2000-US14578	20000525
WO 2000072827	A3	20010125		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6395300	B1	20020528	US 1999-433486	19991104
CA 2371836	AA	20001207	CA 2000-2371836	20000525
EP 1180020	A2	20020220	EP 2000-939365	20000525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010984	A	20020430	BR 2000-10984	20000525
JP 2003500438	T2	20030107	JP 2000-620939	20000525
NZ 516083	A	20030829	NZ 2000-516083	20000525
AU 768022	B2	20031127	AU 2000-54459	20000525
US 2002041896	A1	20020411	US 2001-798824	20010302
US 6610317	B2	20030826		
NO 2001005753	A	20020128	NO 2001-5753	20011126
ZA 2001010347	A	20030730	ZA 2001-10347	20011218

PRIORITY APPLN. INFO.:

US 1999-136323P	P	19990527
US 1999-158659P	P	19991008
US 1999-433486	A	19991104
US 2000-186310P	P	20000302
WO 2000-US14578	W	20000525

AB Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aqueous media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solns., and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. Paclitaxel or docetaxel can be provided in a porous matrix form, which allows the drug to be formulated without solubilizing agents and administered as a bolus. For example, a nifedipine-loaded organic solution was prepared by dissolving 9.09 g of PEG 3350, 2.27 g of nifedipine, and 0.009 g of lecithin in 182 mL of methylene chloride. An aqueous solution was prepared by dissolving 3.27 g of NH4HCO3 and 0.91 g of PEG 3350 in 1.82 mL of water. The aqueous and organic solns. were homogenized and resulting emulsion was spray dried. A suspension of the porous nifedipine drug matrix was prepared in 5% dextrose solution at a concentration of 2.5 mg/mL. A bolus injection of the suspension was tolerated when administrated to dogs.

IT **120014-06-4**, Donepezil
RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of porous matrixes containing hydrophilic polymers and sugars for

enhancement of drug dissoln.)
RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L36 ANSWER 13 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:725499 HCAPLUS
DOCUMENT NUMBER: 133:286505
TITLE: Stabilized compositions containing nootropic drugs
INVENTOR(S): Kato, Akira; Harada, Tsutomu; Murahashi, Naokazu; Sugaya, Yukiko; Ando, Hidenobu
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000059544	A1	20001012	WO 1999-JP1686		19990331
W: US					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
EP 1086706	A1	20010328	EP 1999-910793		19990331
EP 1086706	B1	20031126			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
AT 254928	E	20031215	AT 1999-910793		19990331
PT 1086706	T	20040227	PT 1999-910793		19990331
ES 2211056	T3	20040701	ES 1999-910793		19990331
US 6372760	B1	20020416	US 2001-700342		20010104
PRIORITY APPLN. INFO.:			EP 1999-910793	A	19990331
			WO 1999-JP1686	W	19990331

AB Disclosed are stable nootropic compns., more particularly, stabilized compns. of nootropic drugs and organic acids. Particularly preferable nootropic is donepezil and preferable examples of the organic acids include toxic acid, methanesulfonic acid, benzoic acid, salicylic acid, tartaric acid, citric acid, etc. A blend containing donepezil 5, toxic acid 5, lactose 150, mannitol 200 and hydroxypropyl cellulose 20 g was dissolved in 50 mL water and kneaded with 7 g hydroxypropyl cellulose and the mixture was granulated.
IT **120014-06-4**, Donepezil
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(nootropic compns. containing organic acids as stabilizers)
RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-

piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 14 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:725436 HCAPLUS
DOCUMENT NUMBER: 133:301171
TITLE: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
INVENTOR(S): Chen, Feng-jing; Patel, Manesh V.
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6383471	B1	20020507	US 1999-287043	19990406
CA 2366702	AA	20001012	CA 2000-2366702	20000316
EP 1165048	A1	20020102	EP 2000-916547	20000316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1999-287043 A 19990406
WO 2000-US7342 W 20000316

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025, Tween-20

0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated gastric fluid.

IT **120014-06-4**, Donepezil
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

RN 120014-06-4 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 15 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:608551 HCAPLUS
DOCUMENT NUMBER: 133:213151
TITLE: Pharmaceutical compositions and methods for improved delivery of hydrophobic therapeutic agents
INVENTOR(S): Patel, Manesh V.; Chen, Feng-Jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050007	A1	20000831	WO 2000-US165	20000105
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6294192	B1	20010925	US 1999-258654	19990226
CA 2365536	AA	20000831	CA 2000-2365536	20000105
AU 2000022242	A5	20000914	AU 2000-22242	20000105
AU 771659	B2	20040401		
EP 1158959	A1	20011205	EP 2000-901394	20000105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537317	T2	20021105	JP 2000-600619	20000105

NZ 513810 A 20040227 NZ 2000-513810 20000105
PRIORITY APPLN. INFO.: US 1999-258654 A 19990226
WO 2000-US165 W 20000105

AB The present invention relates to triglyceride-free pharmaceutical compns. for delivery of hydrophobic therapeutic agents. Compns. of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compns. A pharmaceutical composition contained cyclosporin 0.14, Cremophor RH-40 0.41, Arlacel186 0.29, sodium taurocholate 0.26, and propylene glycol 0.46 mg.

IT **120014-06-4**, Donepezil
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 16 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:493363 HCAPLUS
DOCUMENT NUMBER: 133:99570
TITLE: Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
INVENTOR(S): Ehrenpreis, Seymour; Blum, Kenneth
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041686	A1	20000720	WO 2000-US722	20000112

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2363847	AA	20000720	CA 2000-2363847	20000112
EP 1158972	A1	20011205	EP 2000-903252	20000112

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:	US 1999-115724P	P 19990112
	WO 2000-US722	W 20000112

AB A new class of antihypertensive agent is provided by substances that inhibit the breakdown of the endogenous substances, the enkephalins and/or the endorphins. The antihypertensive effect of an enkephalin breakdown inhibitor is greatly enhanced by being combined with a β adrenergic blocking agent. Specifically, D-phenylalanine, an enkephalin breakdown inhibitor when used alone produces excellent blood pressure lowering in animals and man. Use of a combination of D-phenylalanine and the β blocker propranolol provides a greatly enhanced antihypertensive effect in the spontaneously hypertensive rat (SHR). Blood pressure lowering by D-phenylalanine, or the latter combination, is very long-lasting in the SHR and man. If the blood pressure of the rat or human is normal, D-phenylalanine has little or no effect on blood pressure. The hypotensive effect of D-phenylalanine is prevented by pretreating the SHR with naloxone or naltrexone which are specific antagonists of enkephalins or endorphins.

IT **120011-70-3**, E2020
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(enkephalin breakdown- or endorphin breakdown-inhibiting substance for treatment of hypertension, and use with other agents)

RN 120011-70-3 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 17 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2000:314578 HCAPLUS
DOCUMENT NUMBER:	132:318050
TITLE:	Choline esterase inhibitors, alone or with other agents, for treating restless legs syndrome and/or periodic limb movements during sleep, and diagnostic method
INVENTOR(S):	Hedner, Jan; Kraiczi, Holger

PATENT ASSIGNEE(S): Swed.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025821	A1	20000511	WO 1999-SE1979	19991103
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1154795	A1	20011121	EP 1999-957453	19991103
EP 1154795	B1	20050817		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: SE 1998-3760 A 19981104
WO 1999-SE1979 W 19991103

AB A method for treating or preventing the restless legs syndrome and/or the periodic limb movements during sleep comprises administration of a choline esterase inhibitor (CEI) and, optionally, carbamazepine, clonidine, baclofen, hypnotic agent, opioid agonist, and dopaminergic agonist. Administration precedes the onset of sleep at night by from zero to three hours so as to make the CEI exert a therapeutic effect during a major portion of the sleep period. Also disclosed are corresponding pharmaceutical compns. and their use, including compns. comprising a combination of CEI with carbamazepine, clonidine, baclofen, hypnotic agent, opioid agonist, and dopaminergic agonist.

IT **120014-06-4**, Donepezil
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(choline esterase inhibitors, alone or with other agents, for treating restless legs syndrome and/or periodic limb movements during sleep, and diagnostic method)

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 18 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:190908 HCAPLUS
DOCUMENT NUMBER: 132:217148
TITLE: Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes

INVENTOR(S): Nicolodi, Maria; Sicuteri, Federigo
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000015205	A2	20000323	WO 1999-EP6648	19990909
WO 2000015205	A3	20000824		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1304904	B1	20010405	IT 1998-FI208	19980911
AU 9958617	A1	20000403	AU 1999-58617	19990909
EP 1112067	A2	20010704	EP 1999-946150	19990909
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002524498	T2	20020806	JP 2000-569789	19990909
US 6608088	B1	20030819	US 2001-763751	20010507

PRIORITY APPLN. INFO.:
IT 1998-FI208 A 19980911
WO 1999-EP6648 W 19990909

AB Acetylcholinesterase inhibitors having central action are used for the treatment of functional (migraine and primary fibromyalgia) and/or organic [amputation ("phantom limb"), tumoral or traumatic denervation or autoimmune mechanism] central pain syndromes.

IT **120011-70-3**, Donepezil hydrochloride **120014-06-4**, Donepezil
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(acetylcholinesterase inhibitors for pharmaceutical compns. for treatment of functional and/or organic pain syndromes)

RN 120011-70-3 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L36 ANSWER 19 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:169319 HCAPLUS
DOCUMENT NUMBER: 132:212709
TITLE: Pharmaceutical composition containing tarcine for the treatment of neurological diseases
INVENTOR(S): Guittard, George V.; Childers, Jerry D.; Wong, Patrick S. L.; Gumucio, Fernando E.; Kidney, David J.
PATENT ASSIGNEE(S): Alza Corporation, USA
SOURCE: U.S., 16 pp., Cont.-in-part of U.S. 5,698,224.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6036973	A	20000314	US 1997-892995	19970715
US 5698224	A	19971216	US 1994-266045	19940627
CA 2187332	AA	19960104	CA 1995-2187332	19950614
PRIORITY APPLN. INFO.:			US 1994-266045 A2	19940627

AB A dosage form is disclosed for administering 10 ng to 1200 mg tacrine to a patient in need of tacrine therapy. A core comprising 86.15 mg of tacrine hydrochloride, 86.15 mg of mannitol, 7.25 mg of poly(vinylpyrrolidone) and 1.81 mg of magnesium stearate was prepared A semipermeable wall was coated around the individual, sep. cores comprising 80 % cellulose acetate having a 39.8% acetyl content and 20 % poly(vinylpyrrolidone). An exit passageway was drilled through the semipermeable wall connecting the tacrine with the exterior of each dosage form. The exit port had a diameter of 30 mils (0.76 mm) and each dosage form dispensed tacrine for 24 h.

IT **120014-06-4**, Donepezil
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical composition containing tarcine for treatment of neurol. diseases)

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 20 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:161136 HCAPLUS
DOCUMENT NUMBER: 132:203155
TITLE: Method of treating neurodegenerative diseases with Aricept or other cholinesterase inhibitor or cholinergic agonist and a selective cyclooxygenase 2 (COX-2) inhibitor
INVENTOR(S): Block, Gilbert A.; Wold-Olsen, Per
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000012093	A1	20000309	WO 1999-US19654		19990827
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2339140	AA	20000309	CA 1999-2339140		19990827
AU 9955887	A1	20000321	AU 1999-55887		19990827
AU 754719	B2	20021121			
EP 1124555	A1	20010822	EP 1999-942530		19990827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002523461	T2	20020730	JP 2000-567210		19990827
US 6531488	B1	20030311	US 2001-763557		20010222
PRIORITY APPLN. INFO.:			US 1998-98481P	P	19980831
			GB 1998-22698	A	19981016
			WO 1999-US19654	W	19990827

AB A method of treating a neurodegenerative disease, in particular Alzheimer's disease, mild cognitive impairment, or other objective memory impairment, comprises the co-administration of Aricept or other cholinesterase inhibitor or cholinergic agonist and an effective amount of a selective COX-2 inhibitor. COX-2 mRNA was found in the hippocampus of Alzheimer's disease patients.

IT **120011-70-3**, Aricept
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL

(Biological study); USES (Uses)
(Aricept or other cholinesterase inhibitor or cholinergic agonist and selective COX-2 inhibitor for neurodegenerative disease treatment)

RN 120011-70-3 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 21 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:53375 HCAPLUS

DOCUMENT NUMBER: 132:88191

TITLE: Composition and method using a combination of a neurotransmitter release enhancer and an acetylcholinesterase inhibitor for treating neurological disorders

INVENTOR(S): Zaczek, Robert

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000002549	A2	20000120	WO 1999-US15537		19990709
WO 2000002549	A3	20001012			
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
US 6262081 liquid	B1	20010717	US 1999-349906		19990708
AU 9948685	A1	20000201	AU 1999-48685		19990709
PRIORITY APPLN. INFO.:			US 1998-92341P	P	19980710
			WO 1999-US15537	W	19990709

OTHER SOURCE(S): MARPAT 132:88191

AB A method of treating neurol. disorders associated with neurotransmitter deficit in a mammal is provided which comprises administering to the mammal a therapeutically effective amount of a combination of: (i) at least one neurotransmitter release enhancer, and (ii) at least one acetylcholinesterase inhibitor. Compns. and kits containing the above compds. are also provided. The neurotransmitter release inhibitor is e.g.

10,10-bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)anthracenone, and the acetylcholinesterase inhibitor is e.g. donepezil-HCl.

IT **120011-70-3**, Donepezil hydrochloride
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(neurotransmitter release enhancer-acetylcholinesterase inhibitor combination for treating neurol. disorders)

RN 120011-70-3 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L36 ANSWER 22 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:811079 HCAPLUS
DOCUMENT NUMBER: 132:44992
TITLE: Method using a 2-aryl-3-aroylbenzo[b]thiophene and optional acetylcholinesterase inhibitor for increasing levels of acetylcholine
INVENTOR(S): Bryant, Henry Uhlman; Glinn, Michele Annette; Paul, Steven Marc; Wu, Xin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965489	A1	19991223	WO 1999-US12525	19990604
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335295	AA	19991223	CA 1999-2335295	19990604
AU 9943338	A1	20000105	AU 1999-43338	19990604
AU 751158	B2	20020808		
BR 9911220	A	20010306	BR 1999-11220	19990604
TR 200003704	T2	20010621	TR 2000-200003704	19990604
JP 2002518329	T2	20020625	JP 2000-554369	19990604

EP 970695		A1	20000112	EP 1999-304587		19990611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
ZA 2000005887		A	20020722	ZA 2000-5887		20001020
US 6395719		B1	20020528	US 2000-700506		20001114
NO 2000006087		A	20001130	NO 2000-6087		20001130
HR 2000000862		A1	20011031	HR 2000-862		20001214
PRIORITY APPLN. INFO.:				US 1998-89489P	P	19980616
				WO 1999-US12525	W	19990604

combo with donepezil

OTHER SOURCE(S): MARPAT 132:44992

GI



I

AB A method for increasing levels of acetylcholine in mammals comprises administering to a mammal in need thereof, an effective amount of I [R1, R3 = H, Me, (substituted) benzoyl, C(O)-C1-6 alkyl; R2 = pyrrolidin-1-yl, piperidin-1-yl, hexamethyleneimin-1-yl, where R2 is optionally the N-oxide] and, optionally, an acetylcholinesterase inhibitor.

IT **120011-70-3**, Donepezil hydrochloride
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(arylaroylbenzothiophene derivative and optional acetylcholinesterase inhibitor for increasing levels of acetylcholine)

RN 120011-70-3 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 23 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:640499 HCAPLUS
DOCUMENT NUMBER: 131:262634
TITLE: Percutaneously applicable preparation and suppository containing an antidementia medicament
INVENTOR(S): Murahashi, Naokazu; Kato, Akira; Sugaya, Yukiko; Ando, Hidenobu
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 947193	A2	19991006	EP 1999-102863	19990303
EP 947193	A3	20010328		
EP 947193	B1	20050525		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 11315016	A2	19991116	JP 1999-50332	19990226
US 6193993	B1	20010227	US 1999-260614	19990302
EP 1484053	A2	20041208	EP 2004-16220	19990303
EP 1484053	A3	20041222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 296090	E	20050615	AT 1999-102863	19990303
US 6521639	B1	20030218	US 2000-628006	20000728
US 2003027841	A1	20030206	US 2002-214745	20020809
US 6815454	B2	20041109		

PRIORITY APPLN. INFO.:
JP 1998-50567 A 19980303
US 1999-260614 A3 19990302
EP 1999-102863 A3 19990303
US 2000-628006 A3 20000728

AB The present invention provides a percutaneously applicable preparation containing an antidementia medicament, wherein the antidementia medicament is incorporated with a higher alc., a lactate of a higher alc., an ester of a higher fatty acid and a lower alc., or an ester of a fatty acid having 6-18 carbon atoms and propylene glycol. The present invention also provides a rectum applicable preparation containing an antidementia medicament, wherein the antidementia medicament is incorporated with a triglyceride of a fatty acid and/or a water-soluble macromol. Propylene glycol was heated to 60° and denepezil·HCl was dispersed therein. To the dispersion, was added a mixture of cetyl lactate and Plastibase to obtain an oily ointment containing donepezil·HCl 5, cetyl lactate 10, propylene glycol 15, and Plastibase 70 %.

IT **120011-70-3**, Donepezil hydrochloride **120014-06-4**, Donepezil
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(percutaneous prepns. and suppositories containing antidementia drug and absorption promoters)

RN 120011-70-3 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L36 ANSWER 24 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:638338 HCAPLUS
DOCUMENT NUMBER: 131:252581
TITLE: Use of idebenone in combination with acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
INVENTOR(S): Miyamoto, Masaomi; Ohta, Hiroyuki; Goto, Giichi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: U.S., 14 pp., Cont.-in-part of Appl. No. PCT/JP98/00109.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5962535	A	19991005	US 1998-42625	19980317
WO 9831356	A1	19980723	WO 1998-JP109	19980114

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	JP 1997-6147	A	19970117
	US 1997-65597P	P	19971118
	WO 1998-JP109	A2	19980114

OTHER SOURCE(S): MARPAT 131:252581

AB A pharmaceutical composition comprising idebenone in combination with a compound having acetylcholinesterase inhibitory activity is useful for treating or preventing Alzheimer's disease. Ameliorative effects of the combined use of idebenone and 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate on learning deficits was investigated in aged rats.

IT **120011-70-3**, Donepezil hydrochloride
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(idebenone in combination with acetylcholinesterase inhibitor for treatment of Alzheimer's disease)

RN 120011-70-3 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 25 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:613655 HCAPLUS
DOCUMENT NUMBER: 131:248236
TITLE: Combination of a GABAAα5 inverse agonist and an acetylcholinesterase inhibitor for treatment of neurodegenerative diseases
INVENTOR(S): Dawson, Gerard Raphael
PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947131	A2	19990923	WO 1999-GB778	19990316
WO 9947131	A3	19991104		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2323618	AA	19990923	CA 1999-2323618	19990316
AU 9928464	A1	19991011	AU 1999-28464	19990316
AU 753077	B2	20021010		
EP 1061952	A2	20001227	EP 1999-909095	19990316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002506815	T2	20020305	JP 2000-536371	19990316
PRIORITY APPLN. INFO.:			GB 1998-5561 A	19980316
			WO 1999-GB778 W	19990316

AB The present invention relates to a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAAα5 receptor subtype, and the use of the combination in treating neurodegenerative conditions such as Alzheimer's Disease.

IT **120011-70-3**, Donepezil hydrochloride **120014-06-4**, Donepezil
RL: **BAC (Biological activity or effector, except adverse)**; BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(acetylcholinesterase inhibitor; combination of a GABAAα5 inverse agonist and an acetylcholinesterase inhibitor for treatment of neurodegenerative diseases)

RN 120011-70-3 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L36 ANSWER 26 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:253737 HCAPLUS
DOCUMENT NUMBER: 130:329196
TITLE: Anhydrous silicic acid for masking bitter taste in oral pharmaceuticals
INVENTOR(S): Harada, Tsutomu; Ukai, Koji
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11106354	A2	19990420	JP 1997-284268	19971002
PRIORITY APPLN. INFO.:			JP 1997-284268	19971002

AB Use of anhydrous silicic acid for masking bitter taste in oral compns. [syrups, liqs., pastes, gels, emulsions, elixirs] of azelastine-HCl, bunazosin-HCl, bifemelane hydrochloride, homochlorcyclizine hydrochloride, donepezil hydrochloride, calcium pantothenate, nicotinamide or vitamin B1, B2 or B6 is claimed.

IT **120011-70-3**, Donepezil hydrochloride
RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(anhydrous silicic acid for masking bitter taste in oral pharmaceuticals)

RN 120011-70-3 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L36 ANSWER 27 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:253736 HCAPLUS
DOCUMENT NUMBER: 130:301689
TITLE: Compositions containing donepezil and photostabilizers for dementia
INVENTOR(S): Kato, Akiyoshi; Murahashi, Naokazu; Inoue, Yukiko; Ando, Hidenobu
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11106353	A2	19990420	JP 1997-268747	19971001

PRIORITY APPLN. INFO.: JP 1997-268747 19971001

AB Compns. [granules, injections] for dementia comprise donepezil and photostabilizers such as tosylate, mesylate, benzoic acid, salicylic acid, tartaric acid and citric acid.

IT **120014-06-4**, Donepezil
RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(compns. containing donepezil and photostabilizers for dementia)

RN 120014-06-4 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L36 ANSWER 28 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:172592 HCAPLUS

DOCUMENT NUMBER: 130:205148

TITLE: Use of phanquinone for the treatment of Alzheimer's disease

INVENTOR(S): Xilinas, Michel; Gerolymatos, Panayotis Nikolas

PATENT ASSIGNEE(S): P.N. Gerolymatos S.A., Greece

SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909981	A1	19990304	WO 1998-IB1095	19980717
W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 5994323	A	19991130	US 1998-23542	19980213
CA 2301706	AA	19990304	CA 1998-2301706	19980717
AU 9881241	A1	19990316	AU 1998-81241	19980717
AU 741782	B2	20011206		
EP 1007040	A1	20000614	EP 1998-930970	19980717
EP 1007040	B1	20020508		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 9814945	A	20000905	BR 1998-14945	19980717
TR 200000455	T2	20000921	TR 2000-200000455	19980717
JP 2001513558	T2	20010904	JP 2000-507371	19980717
NZ 502565	A	20020301	NZ 1998-502565	19980717
AT 217191	E	20020515	AT 1998-930970	19980717
PT 1007040	T	20021031	PT 1998-930970	19980717
ES 2177024	T3	20021201	ES 1998-930970	19980717
WO 9934807	A1	19990715	WO 1998-IB2115	19981223

W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9915027	A1	19990726	AU 1999-15027	19981223
BG 104179	A	20001031	BG 2000-104179	20000222
BG 64300	B1	20040930		
US 6670369	B1	20031230	US 2000-485909	20001019
HK 1029937	A1	20050311	HK 2001-100873	20010207
US 2005003018	A1	20050106	US 2003-717182	20031118

PRIORITY APPLN. INFO.:	GR 1997-100330	A 19970821
	GR 1997-100507	A 19971231
	GR 1997-970100330	A 19970821
	GR 1997-970100507	A 19971231
	WO 1998-IB1095	W 19980717
	WO 1998-IB2115	W 19981223
	US 2000-485909	A3 20001019

AB The use of phanquinone for the manufacture of a pharmaceutical composition for the prevention or the treatment of Alzheimer's disease is disclosed. Also methods of treatment or prevention of Alzheimer's disease are disclosed.

IT **120014-06-4**, Donepezil
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(phanquinone and other agents for the treatment of Alzheimer's disease)

RN 120014-06-4 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 29 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:141205 HCAPLUS
DOCUMENT NUMBER: 130:205156
TITLE: Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity
INVENTOR(S): Snorrason, Ernir; Murray, James Robert
PATENT ASSIGNEE(S): Shire International Licensing BV, Neth.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9908672	A1	19990225	WO 1998-GB2448		19980814
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9887421	A1	19990308	AU 1998-87421		19980814
ZA 9807316	A	19990315	ZA 1998-7316		19980814
PRIORITY APPLN. INFO.:			GB 1997-17399	A	19970815
			GB 1997-17401	A	19970815
			WO 1998-GB2448	W	19980814

OTHER SOURCE(S): MARPAT 130:205156

AB A pharmaceutically acceptable cholinesterase inhibitor, or a pro-drug therefor, is used in the manufacture of a medicament for combating diseases associated with proteolytic enzyme activity, e.g. psoriasis, osteoarthritis, rheumatoid arthritis, Crohn's disease and ulcerative colitis.

IT **120014-06-4**, Donepezil **120014-06-4D**, Donepezil, prodrugs
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity)

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 30 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:130564 HCAPLUS
DOCUMENT NUMBER: 130:187195
TITLE: Use of cholinesterase inhibitors for treating attention deficit disorders
INVENTOR(S): Snorrason, Ernir; Murray, James Robert
PATENT ASSIGNEE(S): Shire International Licensing B.V., Neth.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9907359	A1	19990218	WO 1998-GB2378	19980807
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2300405	AA	19990218	CA 1998-2300405	19980807
AU 9887367	A1	19990301	AU 1998-87367	19980807
ZA 9807140	A	19990309	ZA 1998-7140	19980807
EP 1001761	A1	20000524	EP 1998-938759	19980807
EP 1001761	B1	20040728		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001513496	T2	20010904	JP 2000-506951	19980807
AT 271865	E	20040815	AT 1998-938759	19980807
ES 2224421	T3	20050301	ES 1998-938759	19980807
TW 577742	B	20040301	TW 1998-87113353	19980813

PRIORITY APPLN. INFO.: GB 1997-16879 A 19970808
WO 1998-GB2378 W 19980807

OTHER SOURCE(S): MARPAT 130:187195

AB The invention provides the use of cholinesterase inhibitors, particularly acetylcholinesterase inhibitors such as galanthamine, in the manufacture of a medicament for combating attention deficit disorders.

IT **120014-06-4**, Donepezil
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)

(galanthamine and other cholinesterase inhibitors for treating attention deficit disorders)

RN 120014-06-4 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 31 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:7823 HCAPLUS

DOCUMENT NUMBER: 130:71564

TITLE: E2020 compositions to reverse mydriasis

INVENTOR(S): York, Billie M.

PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA

SOURCE: PCT Int. Appl., 7 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9856380	A1	19981217	WO 1998-US10780		19980609
W: AU, BR, CA, JP, MX, US					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9877999	A1	19981230	AU 1998-77999		19980609
PRIORITY APPLN. INFO.:			US 1997-49345P	P	19970611
			WO 1998-US10780	W	19980609

GI



I

AB E2020 (I) ophthalmic compns. are used to reverse mydriasis. A composition was prepared containing I 0.25, dibasic Na phosphate 0.50, NaCl 0.60, benzalkonium chloride solution (10%) 0.01 weight% + 3% excess, HCl or NaOH to pH 6.8-7.2 and purified water q.s.

IT **120011-70-3**, E2020 **120014-06-4**, 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-

RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(E2020 compns. to reverse mydriasis)

RN 120011-70-3 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 32 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:7768 HCAPLUS
DOCUMENT NUMBER: 130:61102
TITLE: Method using 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine for reducing side effects of ophthalmic pharmaceuticals.
INVENTOR(S): York, Billie M.
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 8 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856250	A1	19981217	WO 1998-US11952	19980609

W: AU, BR, CA, JP, MX, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9878311 A1 19981230 AU 1998-78311 19980609
PRIORITY APPLN. INFO.: US 1997-49290P P 19970611
WO 1998-US11952 W 19980609

AB Methods and compns. using 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine for reducing locally expressed ophthalmic side effects are disclosed.

IT **120011-70-3 120014-06-4 120014-06-4D**, isomers
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(piperidine derivative for reducing side effects of ophthalmic pharmaceuticals)

RN 120011-70-3 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 33 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:7767 HCAPLUS
DOCUMENT NUMBER: 130:61101
TITLE: Methods and compositions using 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine for enhancing the activity of glaucoma drugs
INVENTOR(S): York, Billie M.
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 8 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9856249	A1	19981217	WO 1998-US11951		19980609
W: AU, BR, CA, JP, MX, US					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9880636	A1	19981230	AU 1998-80636		19980609
PRIORITY APPLN. INFO.:			US 1997-49347P	P	19970611
			WO 1998-US11951	W	19980609

AB Methods and compns. using 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine for enhancing the activity of hydrolyzable glaucoma drugs (e.g. acetylcholine, pilocarpine) are disclosed.

IT **120011-70-3 120014-06-4 120014-06-4D**, isomers
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(piperidine derivative for glaucoma drug activity enhancement)

RN 120011-70-3 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 34 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:682155 HCAPLUS
DOCUMENT NUMBER: 129:293908
TITLE: Oral pharmaceutical preparations decreased in bitterness by masking
INVENTOR(S): Ukai, Koji; Harada, Tsutomu; Suzuki, Yasuyuki
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9843675	A1	19981008	WO 1998-JP1360	19980326
W: KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 974366	A1	20000126	EP 1998-911029	19980326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, SE, IE				
JP 11228450	A2	19990824	JP 1998-80687	19980327
JP 2005041887	A2	20050217	JP 2004-329382	20041112

PRIORITY APPLN. INFO.:	JP 1997-78568	A	19970328
	JP 1997-343265	A	19971212
	WO 1998-JP1360	W	19980326
	JP 1998-80687	A3	19980327

AB Disclosed are oral drug compns. or oral medicines wherein the unpleasant tastes inherent in drugs are masked, specifically, granules, powders and syrups decreased in unpleasant tastes by masking and each containing a basic drug tasting unpleasant and an anionic high-mol. substance such as carrageenan. Donepezil·HCl 0.1, Na saccharin 0.3, and Povidone 14 g were dissolved in 50 g distilled water. The solution was mixed with an aqueous

solution containing κ-carrageenan 0.7 g in 50 g water. To the mixture, methylparaben 0.3 g and propylparaben 0.02 g dissolved in a small amount of propylene glycol were added to obtain a syrup.

IT **120011-70-3**, Donepezil hydrochloride
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(bitterness-masked oral pharmaceuticals by anionic polymers)

RN 120011-70-3 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 35 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:509093 HCAPLUS
DOCUMENT NUMBER: 129:144870
TITLE: Idebenone containing combination agent for treating Alzheimer's disease
INVENTOR(S): Miyamoto, Masaomi; Ohta, Hiroyuki; Goto, Giichi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9831356	A1	19980723	WO 1998-JP109		19980114
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9854953	A1	19980807	AU 1998-54953		19980114
EP 952826	A1	19991103	EP 1998-900361		19980114
EP 952826	B1	20011114			
R: DE					
JP 10259126	A2	19980929	JP 1998-6261		19980116
US 5962535	A	19991005	US 1998-42625		19980317
PRIORITY APPLN. INFO.:			JP 1997-6147	A	19970117
			US 1997-65597P	P	19971118

WO 1998-JP109 W 19980114

OTHER SOURCE(S): MARPAT 129:144870

AB A pharmaceutical composition comprising idebenone in combination with a compound having acetylcholinesterase inhibitory activity is useful for treating or preventing Alzheimer's disease. Ameliorative effect of the combined use of idebenone and donepezil on learning deficits was investigated in aged rats; tests for passive avoidance learning and water maze learning, showed that the drug combination significantly improved the learning deficits in aged rats.

IT **120014-06-4**, Donepezil
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(idebenone and acetylcholinesterase inhibitor combination for treatment of Alzheimer's disease)

RN 120014-06-4 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 36 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:504876 HCAPLUS

DOCUMENT NUMBER: 129:193712

TITLE: Sustained-release microcapsules of acetylcholinesterase inhibitors for Alzheimer's disease

INVENTOR(S): Motodani, Toshio; Ikari, Yasutaka; Miyamoto, Masaomi

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF

DOCUMENT TYPE: **Patent**

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10203966	A2	19980804	JP 1997-320223	19971121
PRIORITY APPLN. INFO.:			JP 1996-311078 A	19961121

AB Sustained-release microcapsules containing acetylcholinesterase inhibitors [i.e. 8-(1-oxo-3-(1-(phenylmethyl)piperidin-4-yl)propyl)-2,2,4,5-tetrahydro-1H-1-benzazepine and 1-benzyl-4-((5,6-dimethoxy-1-oxoindan-2-yl)methyl)piperidine] and biodegradable glycolic acid-lactic acid copolymer for treatment of Alzheimer's disease are claimed. The prepns. showed high bioavailability.

IT **120014-06-4**

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (sustained-release microcapsules of acetylcholinesterase inhibitors for Alzheimer's disease)

RN 120014-06-4 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L36 ANSWER 37 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:490540 HCAPLUS

DOCUMENT NUMBER: 129:131258

TITLE: Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of Alzheimer's disease or other disorders involving cholinergic hypofunction

INVENTOR(S): Schwarz, Roy Douville; Callahan, Michael James

PATENT ASSIGNEE(S): Warner-Lambert Co., USA; Schwarz, Roy Douville; Callahan, Michael James

SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9830243	A1	19980716	WO 1997-US23792		19971229
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9857168	A1	19980803	AU 1998-57168		19971229
ZA 9800118	A	19980708	ZA 1998-118		19980107
PRIORITY APPLN. INFO.:			US 1997-34059P	P	19970108
			US 1997-65886P	P	19971117
			WO 1997-US23792	W	19971229

AB New compns. of matter and a method for treating bodily disorders involving cholinergic hypofunction, e.g. Alzheimer's disease, in a mammal are disclosed. The compns. comprise a combination of an acetylcholinesterase inhibitor and a muscarinic agonist. The method comprises administration of the combination to a mammal. The invention demonstrates that the combination of an acetylcholinesterase inhibitor and a muscarinic agonist can be safely administered, that doses of each agent which by themselves showed no activity yielded pos. responses and minimal side effects in combination, and that the active dose range for both agents could be

widened when used in combination. These results imply that the combined treatment may eliminate the need to individually titrate doses and also increase the separation between efficacy and adverse events.

IT **120014-06-4**, Donepezil
RL: ADV (Adverse effect, including toxicity); **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study);
USES (Uses)
(acetylcholinesterase inhibitor-muscarinic agonist combination for treatment of Alzheimer's disease or other disorder involving cholinergic hypofunction)

RN 120014-06-4 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 38 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:287425 HCAPLUS
DOCUMENT NUMBER: 129:45330
TITLE: Sustained-release implants for treatment of dementia, and their manufacture
INVENTOR(S): Ishida, Mari; Ashizawa, Kazuhide; Murahashi, Naokazu; Ando, Hidenobu
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10120553	A2	19980512	JP 1996-281067	19961023

PRIORITY APPLN. INFO.: JP 1996-281067 19961023

AB The title implants are manufactured by melt mixing antidementia drugs with biodegradable macromols., then solidification. An implant comprising glycolic acid-lactic acid copolymer and donepezil hydrochloride showed good sustained-release properties.

IT **120011-70-3**, Donepezil hydrochloride
RL: BPR (Biological process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process);
USES (Uses)
(sustained-release implants containing biodegradable macromols. for treatment of dementia)

RN 120011-70-3 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-

piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



L36 ANSWER 39 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:25162 HCAPLUS
DOCUMENT NUMBER: 128:97725
TITLE: Therapeutic methods and compositions using R-ibuprofen
INVENTOR(S): Xiaotao, Qian; Hall, Stephen D.
PATENT ASSIGNEE(S): Advanced Research and Technology Institute, USA; Xiaotao, Qian; Hall, Stephen D.
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9748391	A2	19971224	WO 1997-US10762		19970620
WO 9748391	A3	19980129			
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9736415	A1	19980107	AU 1997-36415		19970620
US 6255347	B1	20010703	US 1997-879870		19970620
PRIORITY APPLN. INFO.:			US 1996-20248P	P	19960621
			WO 1997-US10762	W	19970620

AB The invention concerns the use of ibuprofen, a non-steroid anti-inflammatory drug, in the treatment of disease. More particularly, it has been discovered that the R-enantiomer of ibuprofen, previously thought to be inactive, may be used as an antineoplastic agent by inhibiting protein kinase C (PKC α) translocation from cytosol to nuclear and microsomal membranes and also in the prophylactic and therapeutic treatment of Alzheimer's and Alzheimer's related diseases by forming R-Ibuprofen-DAG (diacylglycerols) which activate PKC and thereby promote secretion of APP (amyloid precursor protein).

IT **120011-70-3**, Donepezil hydrochloride
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL

(Biological study); USES (Uses)
(ibuprofen R-enantiomer for treatment of neoplasms and Alzheimer's disease, and use with other agents)

RN 120011-70-3 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L36 ANSWER 40 OF 40 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:21377 HCAPLUS
DOCUMENT NUMBER: 128:97719
TITLE: Use of darifenacin to enhance cognitive functions
INVENTOR(S): Allen, Michael John; Johnson, Brian Frank; Leaker, Brian Robert; Wallis, Robert Michael
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 6 pp.
CODEN: EPXXDW
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 813870	A1	19971229	EP 1997-303879	19970605
EP 813870	B1	20030625		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 243514	E	20030715	AT 1997-303879	19970605
PT 813870	T	20031031	PT 1997-303879	19970605
ES 2197972	T3	20040116	ES 1997-303879	19970605
JP 10059848	A2	19980303	JP 1997-151899	19970610
JP 3453493	B2	20031006		
US 5837724	A	19981117	US 1997-872891	19970611
CA 2208111	AA	19971218	CA 1997-2208111	19970616
CA 2208111	C	20021015		
AU 9724956	A1	19980108	AU 1997-24956	19970617
ZA 9705311	A	19981217	ZA 1997-5311	19970617
PRIORITY APPLN. INFO.:			GB 1996-12710 A	19960618

AB Darifenacin, and its pharmaceutically acceptable salts, are useful in the treatment of cognitive impairment. The invention also discloses the use of combinations of darifenacin, or a pharmaceutically acceptable salt thereof, with an acetylcholinesterase inhibitor (e.g. donepezil), in the treatment of cognitive impairment.

IT **120014-06-4**, Donepezil

RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(darifenacin combination with acetylcholinesterase inhibitor to enhance cognitive functions)

RN 120014-06-4 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



```
=> d his ful

     (FILE 'HOME' ENTERED AT 18:12:02 ON 14 SEP 2005)

     FILE 'REGISTRY' ENTERED AT 18:12:06 ON 14 SEP 2005
L1             STR
L2               8 SEA SSS SAM L1
L3             314 SEA SSS FUL L1

     FILE 'HCAPLUS' ENTERED AT 18:14:19 ON 14 SEP 2005
L4             703 SEA ABB=ON  PLU=ON  L3

     FILE 'REGISTRY' ENTERED AT 18:14:23 ON 14 SEP 2005
L5             STR L1
L6              11 SEA SUB=L3 SSS SAM L5
L7             265 SEA SUB=L3 SSS FUL L5

     FILE 'HCAPLUS' ENTERED AT 18:15:25 ON 14 SEP 2005
L8             702 SEA ABB=ON  PLU=ON  L7

     FILE 'REGISTRY' ENTERED AT 18:15:31 ON 14 SEP 2005
L9             STR L5
L10              4 SEA SUB=L3 SSS SAM L9
L11            135 SEA SUB=L3 SSS FUL L9

     FILE 'HCAPLUS' ENTERED AT 18:16:20 ON 14 SEP 2005
L12            702 SEA ABB=ON  PLU=ON  L11

     FILE 'REGISTRY' ENTERED AT 18:16:34 ON 14 SEP 2005
L13            STR L9
L14             52 SEA SUB=L3 SSS FUL L13

     FILE 'HCAPLUS' ENTERED AT 18:17:58 ON 14 SEP 2005
L15            700 SEA ABB=ON  PLU=ON  L14

     FILE 'REGISTRY' ENTERED AT 18:18:08 ON 14 SEP 2005
L16            STR L13
L17             22 SEA SUB=L3 SSS FUL L16

     FILE 'HCAPLUS' ENTERED AT 18:19:18 ON 14 SEP 2005
L18            697 SEA ABB=ON  PLU=ON  L17

     FILE 'REGISTRY' ENTERED AT 18:19:27 ON 14 SEP 2005

     FILE 'HCAPLUS' ENTERED AT 18:19:46 ON 14 SEP 2005
               E US2003-623577/APPS
L19              2 SEA ABB=ON  PLU=ON  US2003-623577/AP
                 SEL RN

     FILE 'REGISTRY' ENTERED AT 18:20:34 ON 14 SEP 2005
L20             27 SEA ABB=ON  PLU=ON  (1668-85-5/BI OR 321-64-2/BI OR 357-70-0/BI
                    OR 41303-74-6/BI OR 9001-08-5/BI OR 101246-68-8/BI OR
                   120011-70-3/BI OR 120014-06-4/BI OR 120014-07-5/BI OR 120014-08
                   -6/BI OR 120014-09-7/BI OR 120014-10-0/BI OR 120014-11-1/BI OR
                   120014-12-2/BI OR 120014-13-3/BI OR 16088-19-0/BI OR 172602-64-
                   1/BI OR 1953-04-4/BI OR 359785-78-7/BI OR 359785-79-8/BI OR
                   475473-11-1/BI OR 50-23-7/BI OR 51581-32-9/BI OR 52-68-6/BI OR
                   57-47-6/BI OR 86697-68-9/BI OR 9000-81-1/BI)
```

```
     FILE 'HCAPLUS' ENTERED AT 18:20:39 ON 14 SEP 2005
L21           2 SEA ABB=ON  PLU=ON  L19 AND L20
                D IALL HITSTR 1-2
                E DRUG DELIVERY SYSTEMS/CT
L22      196614 SEA ABB=ON  PLU=ON  DRUG DELIVERY SYSTEMS+PFT,NT1/CT
L23         601 SEA ABB=ON  PLU=ON  L17(L)(BAC OR DMA OR PAC OR PKT OR THU)/RL

L24         141 SEA ABB=ON  PLU=ON  L22 AND L23
L25         137 SEA ABB=ON  PLU=ON  L24 AND P/DT
L26           4 SEA ABB=ON  PLU=ON  L24 NOT L25
L27           0 SEA ABB=ON  PLU=ON  L26 NOT PY>2000
L28          40 SEA ABB=ON  PLU=ON  L25 NOT PRD>2000
L29         233 SEA ABB=ON  PLU=ON  L8 AND P/DT
L30         469 SEA ABB=ON  PLU=ON  L8 NOT P/DT
L31         158 SEA ABB=ON  PLU=ON  L30 NOT PY>2000
L32          72 SEA ABB=ON  PLU=ON  L29 NOT PRY>2000
L33         230 SEA ABB=ON  PLU=ON  L31 OR L32
L34         608 SEA ABB=ON  PLU=ON  L7(L)(BAC OR DMA OR PAC OR PKT OR THU)/RL
L35         175 SEA ABB=ON  PLU=ON  L33 AND L34
L36          40 SEA ABB=ON  PLU=ON  L35 AND L22
                D QUE
                D L36 IBIB ABS HITSTR 1-40

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 18:29:01 ON 14 SEP 2005
L37        4140 SEA ABB=ON  PLU=ON  L3
L38        1395 SEA ABB=ON  PLU=ON  L37 NOT PY>2000
L39        1395 SEA ABB=ON  PLU=ON  L7 NOT PY>2000
L40        1395 SEA ABB=ON  PLU=ON  L17 NOT PY>2000
                D KWIC

     FILE 'HCAPLUS, MEDLINE, EMBASE, BIOSIS' ENTERED AT 18:30:41 ON 14 SEP 2005
L41        1125 DUP REM L36 L40 (310 DUPLICATES REMOVED)
                    ANSWERS '1-40' FROM FILE HCAPLUS
                    ANSWERS '41-304' FROM FILE MEDLINE
                    ANSWERS '305-1004' FROM FILE EMBASE
                    ANSWERS '1005-1125' FROM FILE BIOSIS


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   13 SEP 2005  HIGHEST RN 863091-33-2
     DICTIONARY FILE UPDATES:  13 SEP 2005  HIGHEST RN 863091-33-2

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
```

* available and contains the CA role and document type information. *
*   *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

FILE HCAPLUS

FILE COVERS 1907 - 14 Sep 2005 VOL 143 ISS 12
FILE LAST UPDATED: 13 Sep 2005 (20050913/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE MEDLINE
FILE LAST UPDATED: 14 SEP 2005 (20050914/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow promt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE
FILE COVERS 1974 TO 9 Sep 2005 (20050909/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 8 September 2005 (20050908/ED)

FILE RELOADED: 19 October 2003.

=> d que

L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L3 314 SEA FILE=REGISTRY SSS FUL L1
L5 STR



NODE ATTRIBUTES:
CONNECT IS E2 RC AT 13
CONNECT IS E2 RC AT 20
CONNECT IS E1 RC AT 27

CONNECT IS E1 RC AT 28
DEFAULT MLEVEL IS ATOM
GGCAT IS LIN LOC SAT AT 13
GGCAT IS LIN LOC SAT AT 20
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE
L7 265 SEA FILE=REGISTRY SUB=L3 SSS FUL L5
L8 702 SEA FILE=HCAPLUS ABB=ON PLU=ON L7
L16 STR



NODE ATTRIBUTES:
CONNECT IS E3 RC AT 1
CONNECT IS E2 RC AT 2
CONNECT IS E3 RC AT 3
CONNECT IS E3 RC AT 4
CONNECT IS E2 RC AT 5
CONNECT IS E3 RC AT 6
CONNECT IS E3 RC AT 8
CONNECT IS E2 RC AT 9
CONNECT IS E3 RC AT 14
CONNECT IS E2 RC AT 15
CONNECT IS E2 RC AT 16
CONNECT IS E3 RC AT 17
CONNECT IS E2 RC AT 18
CONNECT IS E2 RC AT 19
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
L17 22 SEA FILE=REGISTRY SUB=L3 SSS FUL L16
L22 196614 SEA FILE=HCAPLUS ABB=ON PLU=ON DRUG DELIVERY SYSTEMS+PFT,NT1/CT
L29 233 SEA FILE=HCAPLUS ABB=ON PLU=ON L8 AND P/DT
L30 469 SEA FILE=HCAPLUS ABB=ON PLU=ON L8 NOT P/DT
L31 158 SEA FILE=HCAPLUS ABB=ON PLU=ON L30 NOT PY>2000
L32 72 SEA FILE=HCAPLUS ABB=ON PLU=ON L29 NOT PRY>2000
L33 230 SEA FILE=HCAPLUS ABB=ON PLU=ON L31 OR L32
L34 608 SEA FILE=HCAPLUS ABB=ON PLU=ON L7(L)(BAC OR DMA OR PAC OR

```
               PKT OR THU)/RL
L35          175 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L33 AND L34
L36           40 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L35 AND L22
L40         1395 SEA L17 NOT PY>2000
L41         1125 DUP REM L36 L40 (310 DUPLICATES REMOVED)


=> d l41 ibib abs hit 41-50 1100-1125

L41  ANSWER 41 OF 1125     MEDLINE on STN                DUPLICATE 1
ACCESSION NUMBER:   2000475785     MEDLINE
DOCUMENT NUMBER:    PubMed ID: 10987910
TITLE:              Donepezil in the treatment of Alzheimer disease.
COMMENT:            Comment on: Arch Neurol. 2000 Jan;57(1):94-9. PubMed ID:
                    10634454
AUTHOR:             Deleu D; Hanssens Y
SOURCE:             Archives of neurology, (2000 Sep) 57 (9) 1380.
                    Journal code: 0372436. ISSN: 0003-9942.
PUB. COUNTRY:       United States
DOCUMENT TYPE:      Commentary
                    Letter
LANGUAGE:           English
FILE SEGMENT:       Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH:        200010
ENTRY DATE:         Entered STN: 20001012
                    Last Updated on STN: 20010618
                    Entered Medline: 20001005
RN   120011-70-3 (donepezil)

L41  ANSWER 42 OF 1125     MEDLINE on STN                DUPLICATE 2
ACCESSION NUMBER:   2001143896     MEDLINE
DOCUMENT NUMBER:    PubMed ID: 11098352
TITLE:              Abnormal movements with donepezil in Alzheimer disease.
AUTHOR:             Amouyal-Barkate K; Bagheri-Charabiani H; Montastruc J L;
                    Moulias S; Vellas B
SOURCE:             Annals of pharmacotherapy, (2000 Nov) 34 (11) 1347.
                    Journal code: 9203131. ISSN: 1060-0280.
PUB. COUNTRY:       United States
DOCUMENT TYPE:      (CASE REPORTS)
                    Letter
LANGUAGE:           English
FILE SEGMENT:       Priority Journals
ENTRY MONTH:        200103
ENTRY DATE:         Entered STN: 20010404
                    Last Updated on STN: 20010404
                    Entered Medline: 20010308
RN   120011-70-3 (donepezil)

L41  ANSWER 43 OF 1125     MEDLINE on STN                DUPLICATE 4
ACCESSION NUMBER:   2001078429     MEDLINE
DOCUMENT NUMBER:    PubMed ID: 11129758
TITLE:              Fulminant chemical hepatitis possibly associated with
                    donepezil and sertraline therapy.
AUTHOR:             Verrico M M; Nace D A; Towers A L
CORPORATE SOURCE:   University of Pittsburgh Medical Center, Pennsylvania, USA.
SOURCE:             Journal of the American Geriatrics Society, (2000 Dec) 48
                    (12) 1659-63.
                    Journal code: 7503062. ISSN: 0002-8614.
PUB. COUNTRY:       United States
```

DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200101
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010111

AB OBJECTIVE: To describe a case of fulminant hepatitis possibly related to concomitant donepezil and seratriline therapy. PATIENT AND SETTING: An 83-year-old woman treated in a dementia care facility and later in a tertiary medical center. INTERVENTION AND MANAGEMENT: Discontinuation of donepezil and sertraline therapy with subsequent improvement evidenced by liver biopsy and liver function tests. RESULTS: An older woman with Alzheimer's disease was admitted to a dementia care facility because of aggressive behavior. Treatment with sertraline was initiated in February 1998. Sertraline doses were increased gradually to 200 mg daily by May 1998, and some improvement in behavior was seen. Concomitant therapy with donepezil 5 mg qhs was initiated June 26, 1998. Ten days later, confusion and jaundice were noted. Total bilirubin was 5.6 mg/dL, GGTP was 1,208 IU/L, and alkaline phosphatase was 369 IU/L. Computed tomography revealed cholelithiasis without ductal dilation. Liver, spleen, and pancreas seemed normal. Donepezil and sertraline were discontinued. The patient was admitted to our institution and treated for dehydration. A liver biopsy revealed scattered portal eosinophils and prominent cholestasis consistent with acute chemical hepatitis. The GGTP and total bilirubin of this patient peaked at 2,235 IU/L and 22.6 mg/dL, respectively. The patient improved, and her liver function tests normalized over the next 2 months.

RN **120011-70-3 (donepezil)**; 635-65-4 (Bilirubin); 79617-96-2 (Sertraline)

L41 ANSWER 44 OF 1125 MEDLINE on STN DUPLICATE 5
ACCESSION NUMBER: 2001202480 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11180473
TITLE: Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil.
AUTHOR: Skjerve A; Nygaard H A
CORPORATE SOURCE: Olaviken Behandlingssenter, 5306 Erdal, Bergen, Norway.. arvid,skjerve@hordaland-f.kommune.no
SOURCE: International journal of geriatric psychiatry, (2000 Dec) 15 (12) 1147-51.
Journal code: 8710629. ISSN: 0885-6230.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200104
ENTRY DATE: Entered STN: 20010417
Last Updated on STN: 20010417
Entered Medline: 20010412

AB Sundowning, manifested as a recurring increase in restlessness and agitation in the evening, is described in a 71-year-old man with clinically diagnosed dementia with Lewy bodies. An objective measure of activity using the activity electronic monitoring technique indicated a marked increase in activity level during the evening compared to earlier in the day. After treatment with donepezil, a cholinesterase inhibitor, ratings of behavioural symptoms improved. In addition, there was a marked

reduction in evening activity and an increase in daytime activity. Cognition and parkinsonism also improved. Possible explanations for this finding are discussed.

RN **120011-70-3 (donepezil)**

L41 ANSWER 45 OF 1125 MEDLINE on STN DUPLICATE 6
ACCESSION NUMBER: 2000199619 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10737358
TITLE: No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.
AUTHOR: Wenk G L; Quack G; Moebius H J; Danysz W
CORPORATE SOURCE: Division of Neural Systems, Memory & Aging, University of Arizona, Tucson 85724, USA.. gary@nsma.arizona.edu
CONTRACT NUMBER: AG10546 (NIA)
SOURCE: Life sciences, (2000 Feb 11) 66 (12) 1079-83.
Journal code: 0375521. ISSN: 0024-3205.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200003
ENTRY DATE: Entered STN: 20000413
Last Updated on STN: 20000413
Entered Medline: 20000331
AB The loss of cholinergic neurons within the basal forebrain of patients with Alzheimer's disease (AD) may underlie aspects of the dementia. Excessive activation of N-methyl-D-aspartate (NMDA) receptors may underlie the degeneration of cholinergic cells. New drug therapies have been designed to either enhance cholinergic function by inhibition acetylcholinesterase (AChE), e.g. galanthamine, tetrahydroaminoacridine or donepezil, or by attenuation of NMDA receptor function, e.g. memantine. A combination of these two therapeutic approaches may be more beneficial at slowing the progression of the AD. The current study investigated whether memantine would attenuate the inhibition of AChE produced by these three drugs. The results indicate that these AChE inhibitors do not lose their therapeutic efficacy in combination with memantine. Our in vitro data suggest that the clinical combination of memantine with a reversible AChE inhibitor should be a valuable pharmacotherapeutic approach to dementia.
RN **120011-70-3 (donepezil)**; 19982-08-2 (Memantine); 321-64-2 (Tacrine); 357-70-0 (Galantamine)

L41 ANSWER 46 OF 1125 MEDLINE on STN DUPLICATE 7
ACCESSION NUMBER: 2000319601 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10862247
TITLE: [Extra-pyramidal syndrome induced by donepezil]. Syndrome extrapyramidal sous donepezil.
AUTHOR: Carcenac D; Martin-Hunyadi C; Kiesmann M; Demuynck-Roegel C; Alt M; Kuntzmann F
CORPORATE SOURCE: Hopital de Jour d'Evaluation Geriatrique et Gerontologique Saint-Francois, CHUR de Strasbourg.
SOURCE: Presse medicale (Paris, France : 1983), (2000 May 20) 29 (18) 992-3.
Journal code: 8302490. ISSN: 0755-4982.
PUB. COUNTRY: France
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: French
FILE SEGMENT: Priority Journals

ENTRY MONTH: 200007
ENTRY DATE: Entered STN: 20000720
Last Updated on STN: 20000720
Entered Medline: 20000707

AB BACKGROUND: The cholinergic hypothesis of Alzheimer's disease is the basis of a new class of drugs: acetylcholinesterase inhibitors. These drugs have few side effects, mainly digestive disorders. CASE REPORTS: Extra-pyramidal side effects with severe gait disorders were observed in 3 patients with Alzheimer's dementia treated with donepezil. This drug was associated with paroxetine or a neuroleptic. In 2 of the 3 cases, the extra-pyramidal effects disappeared when donepezil was discontinued. DISCUSSION: Extra-pyramidal syndromes in elderly subjects with cognitive impairment are difficult to interpret. The possible causes include interactions between acetylcholinesterase inhibitors, neuroleptics and serotonine reuptake inhibitors and Lewy body dementia.

RN **120011-70-3 (donepezil)**

L41 ANSWER 47 OF 1125 MEDLINE on STN DUPLICATE 8
ACCESSION NUMBER: 2001032273 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11044869
TITLE: Use of donepezil for the treatment of mild-moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice.
AUTHOR: Cameron I; Curran S; Newton P; Petty D; Wattis J
CORPORATE SOURCE: Consultant in Public Health Medicine, Leeds Health Authority, Leeds, UK.
SOURCE: International journal of geriatric psychiatry, (2000 Oct) 15 (10) 887-91.
Journal code: 8710629. ISSN: 0885-6230.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200011
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001122

AB There have been a number of randomised, placebo-controlled trials of donepezil in the treatment of mild-moderate Alzheimer's disease and these report significant benefits for a proportion of patients. Little is known about the use of donepezil in routine clinical practice. The aims of this study were to examine the use of donepezil in routine clinical practice and to identify some of the practical and resource implications associated with treatment. A number of areas were examined against published guidelines including assessment, diagnosis, initiation of treatment, monitoring and discontinuation of treatment. This was a retrospective case note study involving patients with mild - moderate Alzheimer's disease over a one-year period. One hundred and seventeen patients were commenced on donepezil and 93 successfully completed three months of treatment. Of these, 47% demonstrated an improvement in cognition, activities of daily living or carer observation (or a combination). Compliance with accepted guidelines with respect to assessment, diagnosis and monitoring requires a standardised approach that has both clinical and resource implications.

RN **120011-70-3 (donepezil)**

L41 ANSWER 48 OF 1125 MEDLINE on STN DUPLICATE 9
ACCESSION NUMBER: 2001008461 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10994012
TITLE: Treatment of REM sleep behavior disorder with donepezil: a report of three cases.
AUTHOR: Ringman J M; Simmons J H
CORPORATE SOURCE: Department of Neurology, University of California, Irvine Medical Center, Orange, CA, USA.
CONTRACT NUMBER: 5M01RR00865-24 (NCRR)
SOURCE: Neurology, (2000 Sep 26) 55 (6) 870-1.
Journal code: 0401060. ISSN: 0028-3878.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200010
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001025

AB Three patients with REM behavior disorder whose nocturnal symptoms were markedly improved by treatment with the acetylcholinesterase inhibitor donepezil are reported. Donepezil may have a role in the treatment of REM behavior disorder, possibly through its actions on cholinergic pathways in the brainstem.

RN **120011-70-3 (donepezil)**

L41 ANSWER 49 OF 1125 MEDLINE on STN DUPLICATE 10
ACCESSION NUMBER: 2000478479 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11030219
TITLE: Parkinsonism onset in a patient concurrently using tiapride and donepezil.
AUTHOR: Arai M
CORPORATE SOURCE: The Department of Neurology, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka.
SOURCE: Internal medicine (Tokyo, Japan), (2000 Oct) 39 (10) 863.
Journal code: 9204241. ISSN: 0918-2918.
PUB. COUNTRY: Japan
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200101
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010111

RN **120011-70-3 (donepezil)**; 51012-32-9 (Tiapride)

L41 ANSWER 50 OF 1125 MEDLINE on STN DUPLICATE 11
ACCESSION NUMBER: 2001077403 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11105732
TITLE: The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
AUTHOR: Stahl S M
CORPORATE SOURCE: Clinical Neuroscience Research Center in San Diego and the Department of Psychiatry at the University of California San Diego, USA.
SOURCE: Journal of clinical psychiatry, (2000 Nov) 61 (11) 813-4.
Journal code: 7801243. ISSN: 0160-6689.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200101
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010111
RN **120011-70-3 (donepezil)**; 123441-03-2 (rivastigmine); 357-70-0 (Galantamine)

L41 ANSWER 1100 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1995:517303 BIOSIS
DOCUMENT NUMBER: PREV199598531603
TITLE: Effect of the selective, reversible acetylcholinesterase inhibitor E2020, quantified by DFP antagonism.
AUTHOR(S): Sherman, K. A.
CORPORATE SOURCE: Dep. Pharmacol. Therapy, Univ. S. Fla. Coll. Med., Tampa, FL 33647, USA
SOURCE: Society for Neuroscience Abstracts, (1995) Vol. 21, No. 1-3, pp. 1976.
Meeting Info.: 25th Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 11-16, 1995.
ISSN: 0190-5295.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 5 Dec 1995
Last Updated on STN: 6 Dec 1995
RN 9000-81-1 (ACETYLCHOLINESTERASE)
110119-84-1Q (E2020)
120011-70-3Q (E2020)
55-91-4Q (DFP)
32291-09-1Q (DFP)
185766-21-6Q (DFP)

L41 ANSWER 1101 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1995:243061 BIOSIS
DOCUMENT NUMBER: PREV199598257361
TITLE: Current development of antidementia drugs for Alzheimer disease: Cholinergic drugs.
AUTHOR(S): Homma, Akira
CORPORATE SOURCE: Dep. Psychiatry, Tokyo Metropolitan Inst. Gerontol., Tokyo 173, Japan
SOURCE: Japanese Journal of Pharmacology, (1995) Vol. 67, No. SUPPL. 1, pp. 57P.
Meeting Info.: 68th Annual Meeting of the Japanese Pharmacological Society. Nagoya, Japan. March 25-28, 1995.
CODEN: JJPAAZ. ISSN: 0021-5198.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 9 Jun 1995
Last Updated on STN: 9 Jun 1995
RN 110119-84-1Q (E-2020)
120011-70-3Q (E-2020)

L41 ANSWER 1102 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1995:422680 BIOSIS
DOCUMENT NUMBER: PREV199598436980
TITLE: Docking simulations of inhibitors to free and acylated acetylcholinesterase.
AUTHOR(S): Inoue, A.; Kawai, T.; Wakita, M.; Iimura, Y.; Sugimoto, H.; Kawakami, Y.
CORPORATE SOURCE: Eisai Tsukuba Research Lab., Tsukuba, Ibaraki 300-26, Japan
SOURCE: Abstracts of Papers American Chemical Society, (1995) Vol. 210, No. 1-2, pp. MEDI 232.
Meeting Info.: 210th American Chemical Society National Meeting. Chicago, Illinois, USA. August 20-24, 1995.
CODEN: ACSRAL. ISSN: 0065-7727.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Oct 1995
Last Updated on STN: 3 Oct 1995
RN 9000-81-1 (ACETYLCHOLINESTERASE)
110119-84-1Q (E2020)
120011-70-3Q (E2020)

L41 ANSWER 1103 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1995:327959 BIOSIS
DOCUMENT NUMBER: PREV199598342259
TITLE: A behavioural comparison between the anticholinesterase drugs tacrine and E2020.
AUTHOR(S): Kirkby, D. L.; Jones, D. N. C.; Higgins, G. A.
CORPORATE SOURCE: Glaxo Unit Behavioural Psychopharmacology, Div. Biosci., Univ. Hertfordshire, Hatfield, Herts AL10 9AB, UK
SOURCE: British Journal of Pharmacology, (1994) Vol. 114, No. PROC. SUPPL., pp. 335P.
Meeting Info.: British Pharmacological Society Meeting. London, England, UK. December 14-16, 1994.
CODEN: BJPCBM. ISSN: 0007-1188.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 2 Aug 1995
Last Updated on STN: 2 Aug 1995
RN 321-64-2 (TACRINE)
110119-84-1Q (E2020)
120011-70-3Q (E2020)

L41 ANSWER 1104 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1994:278851 BIOSIS
DOCUMENT NUMBER: PREV199497291851
TITLE: Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020.
AUTHOR(S): Galli, Alessandro [Reprint author]; Mori, Francesca; Benini, Luca; Cacciarelli, Nicola
CORPORATE SOURCE: Dip. Farmacol. Preclin. Clin., Univ. Firenze, V.le G.B. Morgagni 65, 50134 Florence, Italy
SOURCE: European Journal of Pharmacology Environmental Toxicology and Pharmacology Section, (1994) Vol. 3, No. 2-3, pp.

189-193.
ISSN: 0926-6917.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 24 Jun 1994
Last Updated on STN: 25 Jun 1994

AB The reversible noncovalent inhibitor of acetylcholinesterase (R,S)-1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)-methylpiperidine hydrochloride (E2020) was shown to inhibit electric eel acetylcholinesterase with high affinity in a mixed competitive-noncompetitive way (K-i = 8.2 nM; K-i'= 13 nM). The pretreatment of electric eel acetylcholinesterase with E2020 dose-dependently prevented the inactivation of the enzyme by 40 mu-M diisopropylfluorophosphate. The EC-50 for this protective effect (95% confidence limits) was 85 (76-96) nM, whereas under the same conditions E2020 IC-50 was 12.3 (9.6-16) nM. E2020 injected together with atropine sulfate (17.4 mg/kg) into mice at doses in the range of 1.04-6.24 mg/kg 15 min before diisopropylfluorophosphate, caused a dose-dependent increase in diisopropylfluorophosphate LD-50, resulting in protection ratios varying from 3.1 to 9.2. The effectiveness of E2020 antidotal effect was inversely correlated to the time between pretreatment and diisopropylfluorophosphate administration, being maximal when E2020 was injected 15 min, and possibly less than 15 min, before poisoning. From these experiments it is concluded that E2020 exerts a protective action against acute diisopropylfluorophosphate-poisoning in the mouse, presumably by protecting acetylcholinesterase from irreversible inactivation by this agent.

RN 9000-81-1 (ACETYLCHOLINESTERASE)
55-91-4 (DIISOPROPYLFLUOROPHOSPHATE)
110119-84-1Q (E2020)
120011-70-3Q (E2020)
9000-81-1 (EC 3.1.1.7)

L41 ANSWER 1105 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1994:381891 BIOSIS
DOCUMENT NUMBER: PREV199497394891
TITLE: E2020 improves cognition and quality of life in patients with mild-to-moderate Alzheimer's disease: Results of a phase-II trial.
AUTHOR(S): Rogers, Sharon L.; Friedhoff, Lawrence T.
CORPORATE SOURCE: Teaneck, NJ, USA
SOURCE: Neurology, (1994) Vol. 44, No. 4 SUPPL. 2, pp. A165.
Meeting Info.: 46th Annual Meeting of the American Academy of Neurology. Washington, D.C., USA. May 1-7, 1994.
CODEN: NEURAI. ISSN: 0028-3878.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 31 Aug 1994
Last Updated on STN: 1 Sep 1994

RN 110119-84-1Q (E2020)
120011-70-3Q (E2020)
9000-81-1 (ACETYLCHOLINESTERASE)

L41 ANSWER 1106 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1993:380841 BIOSIS
DOCUMENT NUMBER: PREV199345052266

TITLE: Effects of systemic cholinesterase inhibitors, tacrine (THA) and E2020, on basal acetylcholine release from rat hippocampus.
AUTHOR(S): Sato, Akio; Suzuki, Takeshi; Fujimoto, Kazuko; Kawashima, Kochiro
CORPORATE SOURCE: Dep. Pharmacol., Kyoritsu Coll. Pharm., Tokyo 105, Japan
SOURCE: Japanese Journal of Pharmacology, (1993) Vol. 61, No. SUPPL. 1, pp. 149P.
Meeting Info.: 66th Annual Meeting of the Japanese Pharmacological Society. Yokohama, Japan. March 24-27, 1993.
CODEN: JJPAAZ. ISSN: 0021-5198.
DOCUMENT TYPE: Conference; (Meeting)
LANGUAGE: English
ENTRY DATE: Entered STN: 12 Aug 1993
Last Updated on STN: 3 Jan 1995
RN 9001-08-5 (CHOLINESTERASE)
321-64-2 (TACRINE)
110119-84-1Q (E2020)
120011-70-3Q (E2020)
51-84-3 (ACETYLCHOLINE)

L41 ANSWER 1107 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1993:196902 BIOSIS
DOCUMENT NUMBER: PREV199344093152
TITLE: Mouse brain localization of new fluorine-18 benzovesamicol tracer is not changed by pre-treatment with sigma ligands haldol, 3-PPP or E2020.
AUTHOR(S): Holland, G. K. [Reprint author]; Sherman, P. S.; Kilbourn, M. R.; Jung, Y.-W.; Frey, K. A.; Wieland, D. M.; Kuhl, D. E.
CORPORATE SOURCE: Div. Nuclear Med., Dep. Internal Med., Univ. Mich. Sch. Med., Ann Arbor, MI 48109, USA
SOURCE: Society for Neuroscience Abstracts, (1992) Vol. 18, No. 1-2, pp. 1467.
Meeting Info.: 22nd Annual Meeting of the Society for Neuroscience. Anaheim, California, USA. October 25-30, 1992.
ISSN: 0190-5295.
DOCUMENT TYPE: Conference; (Meeting)
LANGUAGE: English
ENTRY DATE: Entered STN: 16 Apr 1993
Last Updated on STN: 9 Jun 1993
RN 13981-56-1 (FLUORINE-18)
52-86-8 (HALDOL)
75240-91-4 (3-PPP)
110119-84-1Q (E2020)
120011-70-3Q (E2020)
51-84-3 (ACETYLCHOLINE)
9012-78-6 (CHOLINE ACETYLTRANSFERASE)
97-39-2 (DI-O-TOLYLGUANIDINE)

L41 ANSWER 1108 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1993:69194 BIOSIS
DOCUMENT NUMBER: PREV199344034844
TITLE: Validation and application of an HPLC method for the determination of 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-

yl)methylpiperidine hydrochloride (E2020) in human plasma.
AUTHOR(S): Lee, J. W. [Reprint author]; Rogers, S. L.; Friedhoff, L. T.; Stiles, M. R. [Reprint author]; Cooper, N. M. [Reprint author]
CORPORATE SOURCE: Harris Lab. Inc., Lincoln, Nebr, USA
SOURCE: Pharmaceutical Research (New York), (1992) Vol. 9, No. 10 SUPPL., pp. S350.
Meeting Info.: American Association of Pharmaceutical Scientists 1992 Annual Meeting and Exposition. San Antonio, Texas, USA. November 15-19, 1992.
CODEN: PHREEB. ISSN: 0724-8741.
DOCUMENT TYPE: Conference; (Meeting)
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Jan 1993
Last Updated on STN: 17 Mar 1993
RN 110119-84-1Q (E2020)
120011-70-3Q (E2020)

L41 ANSWER 1109 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1993:69147 BIOSIS
DOCUMENT NUMBER: PREV199344034797
TITLE: A radioenzyme assay of acetylcholinesterase activity in red blood cells and its correlation with 1-benzyl-4((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine hydrochloride (E2020).
AUTHOR(S): Hulse, J. D. [Reprint author]; Rogers, S. L.; Friedhoff, L. T.; Sukovaty, R. [Reprint author]; Pedersen, J. E. [Reprint author]; Lee, J. W. [Reprint author]
CORPORATE SOURCE: Harris Lab., Lincoln, Nebraska, USA
SOURCE: Pharmaceutical Research (New York), (1992) Vol. 9, No. 10 SUPPL., pp. S338.
Meeting Info.: American Association of Pharmaceutical Scientists 1992 Annual Meeting and Exposition. San Antonio, Texas, USA. November 15-19, 1992.
CODEN: PHREEB. ISSN: 0724-8741.
DOCUMENT TYPE: Conference; (Meeting)
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Jan 1993
Last Updated on STN: 17 Mar 1993
RN 9000-81-1 (ACETYLCHOLINESTERASE)
110119-84-1Q (E2020)
120011-70-3Q (E2020)

L41 ANSWER 1110 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1993:69146 BIOSIS
DOCUMENT NUMBER: PREV199344034796
TITLE: Distribution of 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine hydrochloride (E2020) in human plasma and red blood cells and its correlation with cholinesterase (ChE) activities.
AUTHOR(S): Rogers, S. L. [Reprint author]; Friedhoff, L. T. [Reprint author]; Sukovaty, R. L.; Pedersen, J. E.; Lee, J. W.
CORPORATE SOURCE: Eisai American Inc., Teaneck, N.J, USA
SOURCE: Pharmaceutical Research (New York), (1992) Vol. 9, No. 10 SUPPL., pp. S338.
Meeting Info.: American Association of Pharmaceutical Scientists 1992 Annual Meeting and Exposition. San Antonio,

Texas, USA. November 15-19, 1992.
CODEN: PHREEB. ISSN: 0724-8741.
DOCUMENT TYPE: Conference; (Meeting)
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Jan 1993
Last Updated on STN: 17 Mar 1993
RN 110119-84-1Q (E2020)
120011-70-3Q (E2020)
9001-08-5 (CHOLINESTERASE)

L41 ANSWER 1111 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1992:426540 BIOSIS
DOCUMENT NUMBER: PREV199243070690; BR43:70690
TITLE: E2030 A NOVEL ACETYLCHOLINESTERASE INHIBITOR 2. COMPARISON OF ACTIONS TO INDUCE YAWNING IN RATS.
AUTHOR(S): UCHIKOSHI K [Reprint author]; OGURA H; KOSASA T; YAMANISHI Y; KANEKO T
CORPORATE SOURCE: TSUKUBA RES LAB, EISAI CO LTD, TSUKUBA-SHI, IBARAKI 300-26, JPN
SOURCE: Japanese Journal of Pharmacology, (1992) Vol. 59, No. SUPPL. 1, pp. 306P.
Meeting Info.: 65TH ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY, SENDAI, JAPAN, MARCH 22-25, 1992.
JPN J PHARMACOL.
CODEN: JJPAAZ. ISSN: 0021-5198.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 14 Sep 1992
Last Updated on STN: 10 Nov 1992
RN 142007-70-3 (E2030)
9000-81-1 (ACETYLCHOLINESTERASE)
110119-84-1Q (E2020)
120011-70-3Q (E2020)
51-34-3 (SCOPOLAMINE)
13265-10-6 (METHYLSCOPOLAMINE)
52-86-8 (HALOPERIDOL)

L41 ANSWER 1112 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1992:491651 BIOSIS
DOCUMENT NUMBER: PREV199243100851; BR43:100851
TITLE: THE PHARMACOKINETICS PK AND PHARMACODYNAMICS PD OF E2020 R S-1 BENZYL-4-5 6-DIMETHOXY-1-INDANON-2-YLMETHYLPIPERDINE HYDROCHLORIDE A NOVEL INHIBITOR OF ACETYLCHOLINESTERASE ACHE IMPLICATIONS FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE.
AUTHOR(S): ROGERS S L [Reprint author]; WALTERS E J; FRIEDHOFF L T
CORPORATE SOURCE: EISAI AMERICA INC, TEANECK, NJ, USA
SOURCE: Neurobiology of Aging, (1992) Vol. 13, No. SUPPL. 1, pp. S125-S126.
Meeting Info.: THIRD INTERNATIONAL CONFERENCE ON ALZHEIMER'S DISEASE AND RELATED DISORDERS, ABANO TERME, ITALY, JULY 12-17, 1992. NEUROBIOL AGING.
CODEN: NEAGDO. ISSN: 0197-4580.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH

ENTRY DATE: Entered STN: 3 Nov 1992
Last Updated on STN: 13 Dec 1992
RN 110119-84-1Q (E2020)
120011-70-3Q (E2020)
9000-81-1 (ACETYLCHOLINESTERASE)

L41 ANSWER 1113 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1992:491645 BIOSIS
DOCUMENT NUMBER: PREV199243100845; BR43:100845
TITLE: THE EFFECTS OF ACETYLCHOLINESTERASE INHIBITORS ON ACETYLCHOLINESTERASE IN SENILE PLAQUE.
AUTHOR(S): NAKAMURA S [Reprint author]; YUKAWA M; MIMORI Y
CORPORATE SOURCE: THIRD DEP INTERN MED, HIROSHIMA UNIV SCH MED, KASUMI 1-2-3, MINAMIKU, HIROSHIMA 734, JAPAN
SOURCE: Neurobiology of Aging, (1992) Vol. 13, No. SUPPL. 1, pp. S124.
Meeting Info.: THIRD INTERNATIONAL CONFERENCE ON ALZHEIMER'S DISEASE AND RELATED DISORDERS, ABANO TERME, ITALY, JULY 12-17, 1992. NEUROBIOL AGING.
CODEN: NEAGDO. ISSN: 0197-4580.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 3 Nov 1992
Last Updated on STN: 13 Dec 1992
RN 9000-81-1 (ACETYLCHOLINESTERASE)
57-47-6 (PHYSOSTIGMINE)
90043-86-0 (AMIRIDIN)
27848-84-6 (NICERGOLINE)
110119-84-1Q (E-2020)
120011-70-3Q (E-2020)

L41 ANSWER 1114 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1992:129229 BIOSIS
DOCUMENT NUMBER: PREV199242056929; BR42:56929
TITLE: E2020 THE PHARMACOLOGY OF A PIPERIDINE CHOLINESTERASE INHIBITOR.
AUTHOR(S): ROGERS S L [Reprint author]; YAMANISHI Y; YAMATSU K
CORPORATE SOURCE: EISAI AMERICA INC, TEANECK, NJ, USA
SOURCE: (1991) pp. 314-320. BECKER, R. AND E. GIACOBINI (ED.). ADVANCES IN ALZHEIMER DISEASE THERAPY SERIES: CHOLINERGIC BASIS FOR ALZHEIMER THERAPY. X+494P. BIRKHAEUSER BOSTON: CAMBRIDGE, MASSACHUSETTS, USA; BASEL, SWITZERLAND. ILLUS. ISBN: 0-8176-3566-1, 3-7643-3566-1.
DOCUMENT TYPE: Book
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 5 Mar 1992
Last Updated on STN: 14 Apr 1992
RN 110119-84-1Q (E2020)
120011-70-3Q (E2020)
57-47-6 (PHYSOSTIGMINE)
9000-81-1 (ACETYLCHOLINESTERASE)
9001-08-5 (BUTYRYLCHOLINESTERASE)

L41 ANSWER 1115 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 1992:129230 BIOSIS
DOCUMENT NUMBER: PREV199242056930; BR42:56930
TITLE: PHARMACODYNAMICS OF ORAL E2020 AND TACRINE IN HUMANS NOVEL APPROACHES.
AUTHOR(S): SHERMAN K A [Reprint author]
CORPORATE SOURCE: DEP PHARMACOL, SOUTHERN ILLINOIS UNIV SCH MED, SPRINGFIELD, ILL, USA
SOURCE: (1991) pp. 321-328. BECKER, R. AND E. GIACOBINI (ED.). ADVANCES IN ALZHEIMER DISEASE THERAPY SERIES: CHOLINERGIC BASIS FOR ALZHEIMER THERAPY. X+494P. BIRKHAEUSER BOSTON: CAMBRIDGE, MASSACHUSETTS, USA; BASEL, SWITZERLAND. ILLUS. ISBN: 0-8176-3566-1, 3-7643-3566-1.
DOCUMENT TYPE: Book
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 5 Mar 1992
Last Updated on STN: 6 Mar 1992
RN 110119-84-1Q (E2020)
120011-70-3Q (E2020)
321-64-2 (TACRINE)
57-47-6 (PHYSOSTIGMINE)
9000-81-1 (ACETYLCHOLINESTERASE)

L41 ANSWER 1116 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1992:129225 BIOSIS
DOCUMENT NUMBER: PREV199242056925; BR42:56925
TITLE: THE SECOND GENERATION OF CHOLINESTERASE INHIBITORS PHARMACOLOGICAL ASPECTS.
AUTHOR(S): GIACOBINI E [Reprint author]
CORPORATE SOURCE: DEP PHARMACOL, SOUTHERN ILLINOIS UNIV SCH MED, SPRINGFIELD, ILL 62794, USA
SOURCE: (1991) pp. 247-262. BECKER, R. AND E. GIACOBINI (ED.). ADVANCES IN ALZHEIMER DISEASE THERAPY SERIES: CHOLINERGIC BASIS FOR ALZHEIMER THERAPY. X+494P. BIRKHAEUSER BOSTON: CAMBRIDGE, MASSACHUSETTS, USA; BASEL, SWITZERLAND. ILLUS. ISBN: 0-8176-3566-1, 3-7643-3566-1.
DOCUMENT TYPE: Book
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 5 Mar 1992
Last Updated on STN: 6 Mar 1992
RN 9001-08-5 (CHOLINESTERASE)
57-47-6 (PHYSOSTIGMINE)
81732-65-2 (BAMBUTEROL)
52-68-6 (METRIFONATE)
110119-84-1Q (E-2020)
120011-70-3Q (E-2020)

L41 ANSWER 1117 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1992:246519 BIOSIS
DOCUMENT NUMBER: PREV199242116819; BR42:116819
TITLE: EFFECT OF ORAL ADMINISTRATION OF REVERSIBLE INHIBITORS ON BLOOD ACETYLCHOLINESTERASE IN HUMANS E2020 AND TACRINE.
AUTHOR(S): SHERMAN K A [Reprint author]
CORPORATE SOURCE: DEP PHARMACOL, SIU SCH, MED, SPRINGFIELD, ILL 62794-9230, USA
SOURCE: Society for Neuroscience Abstracts, (1991) Vol. 17, No.

1-2, pp. 1235.
Meeting Info.: 21ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, NEW ORLEANS, LOUISIANA, USA, NOVEMBER 10-15, 1991. SOC NEUROSCI ABSTR.
ISSN: 0190-5295.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 14 May 1992
Last Updated on STN: 15 May 1992
RN 9000-81-1 (ACETYLCHOLINESTERASE)
110119-84-1Q (E2020)
120011-70-3Q (E2020)
321-64-2 (TACRINE)

L41 ANSWER 1118 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1990:304099 BIOSIS
DOCUMENT NUMBER: PREV199039022280; BR39:22280
TITLE: E-2020 A NOVEL CENTRALLY-ACTING ACETYLCHOLINESTERASE INHIBITOR 4 COMPARISON OF THE EFFECTS OF SINGLE AND REPEATED ADMINISTRATION ON CEREBRAL CHOLINERGIC SYSTEM IN RATS.
AUTHOR(S): KOSASA T [Reprint author]; OGURA H; UCHIKOSHI K; ARAKI S; YAMANISHI Y; YAMATSU K
CORPORATE SOURCE: EISAI TSUKUBA RES LAB, 5-1-3 TOKODAI, TSUKUBA-CITY, IBARAKI 300-26, JPN
SOURCE: Japanese Journal of Pharmacology, (1990) Vol. 52, No. SUPPL. 1, pp. 359P.
Meeting Info.: 63RD ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY, TOKYO, JAPAN, MARCH 25-28, 1990. JPN J PHARMACOL.
CODEN: JJPAAZ. ISSN: 0021-5198.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 27 Jun 1990
Last Updated on STN: 10 Jul 1990
RN 110119-84-1Q (E-2020)
120011-70-3Q (E-2020)
9000-81-1 (ACETYLCHOLINESTERASE)

L41 ANSWER 1119 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1991:85690 BIOSIS
DOCUMENT NUMBER: PREV199140039675; BR40:39675
TITLE: NEW METHODS TO DETERMINE IN-VIVO ACTION OF REVERSIBLE ACETYLCHOLINESTERASE INHIBITORS TACRINE AND E-2020.
AUTHOR(S): SHERMAN K A [Reprint author]
CORPORATE SOURCE: DEP PHARMACOL, SOUTHERN ILL UNIV SCH MED, SPRINGFIELD, ILL, USA
SOURCE: Society for Neuroscience Abstracts, (1990) Vol. 16, No. 1, pp. 137.
Meeting Info.: 20TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, ST. LOUIS, MISSOURI, USA, OCTOBER 28-NOVEMBER 2, 1990. SOC NEUROSCI ABSTR.
ISSN: 0190-5295.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR

LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 2 Feb 1991
Last Updated on STN: 7 Mar 1991
RN 9000-81-1 (ACETYLCHOLINESTERASE)
321-64-2 (TACRINE)
110119-84-1Q (E-2020)
120011-70-3Q (E-2020)
55-91-4Q (DFP)
32291-09-1Q (DFP)
185766-21-6Q (DFP)

L41 ANSWER 1120 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1989:395762 BIOSIS
DOCUMENT NUMBER: PREV198937062410; BR37:62410
TITLE: EFFECT OF CHOLINERGIC DRUGS ON THE HYPERLOCOMOTION IN THE NUCLEUS BASALIS MAGNOCELLULARIS LESIONED RAT.
AUTHOR(S): KUBOTA A [Reprint author]; UCHIKOSHI K; KOSASA M; YAMANISHI Y; YAMATSU K
CORPORATE SOURCE: EISAI TSUKUBA RES LAB, 5-1-3 TOKODAI, TSUKUBA-CITY, IBARAKI 300-26, JPN
SOURCE: Japanese Journal of Pharmacology, (1989) Vol. 49, No. SUPPL, pp. 334P.
Meeting Info.: 62ND GENERAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, JAPAN, MARCH 25-28, 1989.
JPN J PHARMACOL.
CODEN: JJPAAZ. ISSN: 0021-5198.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 22 Aug 1989
Last Updated on STN: 23 Sep 1989
RN 57-47-6 (PHYSOSTIGMINE)
63-75-2 (ARECOLINE)
110119-84-1Q (E-2020)
120011-70-3Q (E-2020)

L41 ANSWER 1121 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1989:395662 BIOSIS
DOCUMENT NUMBER: PREV198937062310; BR37:62310
TITLE: E-2020 A NOVEL CENTRALLY ACTING ACETYLCHOLINESTERASE INHIBITOR 2 NEUROCHEMICAL STUDIES OF ACETYLCHOLINE METABOLISM.
AUTHOR(S): YAMANISHI Y [Reprint author]; KOSASA T; OGURA H; ARAKI S; YAMATSU K
CORPORATE SOURCE: EISAI TSUKUBA RES LAB, 5-3-1 TOKODAI, TSUKUBA-CITY, IBARAKI 300-26, JPN
SOURCE: Japanese Journal of Pharmacology, (1989) Vol. 49, No. SUPPL, pp. 301P.
Meeting Info.: 62ND GENERAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, JAPAN, MARCH 25-28, 1989.
JPN J PHARMACOL.
CODEN: JJPAAZ. ISSN: 0021-5198.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 22 Aug 1989
Last Updated on STN: 23 Sep 1989

RN 110119-84-1Q (E-2020)
120011-70-3Q (E-2020)
9000-81-1 (ACETYLCHOLINESTERASE)
51-84-3 (ACETYLCHOLINE)
51-34-3 (SCOPOLAMINE)
57-47-6 (PHYSOSTIGMINE)

L41 ANSWER 1122 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1989:395232 BIOSIS
DOCUMENT NUMBER: PREV198937061880; BR37:61880
TITLE: E-2020 A NOVEL CENTRALLY ACTING ACETYLCHOLINESTERASE INHIBITOR 1. INHIBITORY ACTION ON CHOLINESTERASE.
AUTHOR(S): ARAKI S [Reprint author]; YAMANISHI Y; KOSASA T; OGURA H; YAMATSU K
CORPORATE SOURCE: EISAI TSUKUBA RES LAB, 5-1-3 TOKODAI, TSUKUBA-CITY, IBARAKI 300-26, JPN
SOURCE: Japanese Journal of Pharmacology, (1989) Vol. 49, No. SUPPL, pp. 155P.
Meeting Info.: 62ND GENERAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, JAPAN, MARCH 25-28, 1989.
JPN J PHARMACOL.
CODEN: JJPAAZ. ISSN: 0021-5198.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 22 Aug 1989
Last Updated on STN: 23 Sep 1989
RN 110119-84-1Q (E-2020)
120011-70-3Q (E-2020)
9000-81-1 (ACETYLCHOLINESTERASE)
9001-08-5 (CHOLINESTERASE)

L41 ANSWER 1123 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1989:395233 BIOSIS
DOCUMENT NUMBER: PREV198937061881; BR37:61881
TITLE: E-2020 A NOVEL CENTRALLY ACTING ACETYLCHOLINESTERASE INHIBITOR 3. BEHAVIORAL STUDY OF CHOLINERGIC ACTION IN RATS.
AUTHOR(S): OGURA H [Reprint author]; KOSASA T; ARAKI S; YAMANISHI Y; YAMATSU K
CORPORATE SOURCE: EISAI TSUKUBA RES LAB 5-1-3 TOKODAI, TSUKUBA-CITY, IBARAKI 300-26, JPN
SOURCE: Japanese Journal of Pharmacology, (1989) Vol. 49, No. SUPPL, pp. 155P.
Meeting Info.: 62ND GENERAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, JAPAN, MARCH 25-28, 1989.
JPN J PHARMACOL.
CODEN: JJPAAZ. ISSN: 0021-5198.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 22 Aug 1989
Last Updated on STN: 23 Sep 1989
RN 110119-84-1Q (E-2020)
120011-70-3Q (E-2020)
9000-81-1 (ACETYLCHOLINESTERASE)

L41 ANSWER 1124 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1988:498541 BIOSIS
DOCUMENT NUMBER: PREV198835117376; BR35:117376
TITLE: BEHAVIORAL STUDY OF E-2020 A NOVEL CENTRALLY ACTING ACETYLCHOLINESTERASE INHIBITOR.
AUTHOR(S): OGURA H [Reprint author]; KOSASA T; ARAKI S; YAMANISHI Y; YAMATSU K
CORPORATE SOURCE: EISAI TSUKUBA RES LAB, 5-1-3 TOKODAI, TSUKUBA-CITY, IBARAKI 300-26, JPN
SOURCE: Society for Neuroscience Abstracts, (1988) Vol. 14, No. 1, pp. 60.
Meeting Info.: 18TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, TORONTO, ONTARIO, CANADA, NOVEMBER 13-18, 1988. SOC NEUROSCI ABSTR.
ISSN: 0190-5295.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 7 Nov 1988
Last Updated on STN: 7 Nov 1988
RN 110119-84-1Q (E-2020)
120011-70-3Q (E-2020)
9000-81-1 (ACETYLCHOLINESTERASE)

L41 ANSWER 1125 OF 1125 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1988:498540 BIOSIS
DOCUMENT NUMBER: PREV198835117375; BR35:117375
TITLE: NEUROCHEMICAL STUDIES OF E-2020 A NOVEL CENTRALLY ACTING ACETYLCHOLINESTERASE INHIBITOR.
AUTHOR(S): YAMANISHI Y [Reprint author]; ARAKI S; KOSASA T; OGURA H; YAMATSU K
CORPORATE SOURCE: EISAI TSUKUBA RES LAB, 5-1-3 TOKODAI, TSUKUBA-CITY, IBARAKI 300-26, JPN
SOURCE: Society for Neuroscience Abstracts, (1988) Vol. 14, No. 1, pp. 59.
Meeting Info.: 18TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, TORONTO, ONTARIO, CANADA, NOVEMBER 13-18, 1988. SOC NEUROSCI ABSTR.
ISSN: 0190-5295.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 7 Nov 1988
Last Updated on STN: 7 Nov 1988
RN 110119-84-1Q (E-2020)
120011-70-3Q (E-2020)
9000-81-1 (ACETYLCHOLINESTERASE)
57-47-6 (PHYSOSTIGMINE)

See Structure next page

L42 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 120011-70-3 REGISTRY
ED Entered STN: 07 Apr 1989
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Aricept
CN BNAG
CN Donepezil hydrochloride
CN E 2020
CN E 2020 (pharmaceutical)
DR 142057-77-0
MF C24 H29 N O3 . Cl H
CI COM
SR CA
LC STN Files: ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DIOGENES, EMBASE, IMSCOSEARCH, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (120014-06-4)



Structure for "E 2020"

● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

250 REFERENCES IN FILE CA (1907 TO DATE)
14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
252 REFERENCES IN FILE CAPLUS (1907 TO DATE)

THIS PAGE IS BLANK